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ABSTRACT
The mouse agouti protein is transiently expressed in the skin and signals
through the melanocortin 1 receptor to switch pigment production of hair-follicle
melanocytes from black to yellow. Ubiquitous over-expression of agouti protein
in mice carrying the spontaneous dominant mutations Ay and Avy causes a
pleiotropic syndrome characterized by solid yellow hair color, obesity, diabetes,
and increased susceptibility to carcinogenesis in a wide variety of tissues,
including the skin. Over-expression of agouti in the skin of keratin 14 (K14)Agouti transgenic mice promotes skin carcinogenesis, even in the absence of
obesity and diabetes. In this study cDNA microarray and qRT-PCR analyses are
used to identify molecular changes in the skin of K14-Agouti mice associated
with the promotion stage of carcinogenesis. Histological analysis of the skin
revealed that there were no differences in gross morphology or in timing of hairfollicle stages between transgenic and control mice. However, cDNA microarray
analysis identified 181 genes with significantly altered expression levels in the
skin of transgenic mice. Additionally, qRT-PCR analysis demonstrated that the
levels and temporal patterns of expression of 10 genes previously associated with
skin and/or other epithelial cancers were significantly altered in the skin of K14Agouti transgenic mice. Agouti-induced over-expression of these protooncogenes in the skin of K14-Agouti mice is proposed to be associated with the
increased susceptibility to skin carcinogenesis. A hypothetical model is presented
to explain the mechanism of action of the agouti protein as a tumor promoter in
skin carcinogenesis. Additionally, strategies for future follow-on experiments to
further investigate the role of agouti in tumor promotion and to test aspects of
the proposed hypothetical model are discussed.
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CHAPTER I
BACKGROUND AND SIGNIFICANCE
Agouti is a paracrine-acting signaling molecule that is normally expressed
only in the skin of mice, where it regulates coat color pigmentation. Ubiquitous
over-expression of wild-type agouti protein in mice carrying spontaneous
dominant agouti mutations results in solid yellow hair color, obesity, diabetes,
and increased susceptibility to carcinogenesis in a wide variety of tissues,
including the skin. In transgenic mice in which the agouti protein is overexpressed in the skin under the regulatory control of the keratin 14 promoter
(K14-Agouti mice), body weight and blood glucose levels are normal, but
transgenic mice are significantly more susceptible to skin cancer and it was
shown that agouti acts as a tumor promoter in two-stage skin carcinogenesis
experiments. The goal of this study was to determine the molecular level changes
associated with the promotion stage of skin carcinogenesis in the uninitiated skin
of K14-Agouti mice. Since tumor promotion is a reversible and rate-limiting step
in carcinogenesis, understanding the molecular changes associated with tumor
promotion may lead to strategies for the treatment and prevention of cancer.
Microarray and qRT-PCR experiments were performed to determine the
expression profiles of genes in the skin of K14-Agouti and control mice at
different ages and at different stages of the hair-follicle cycle. Genes known to be
associated with skin cancer and other epithelial cancers are shown to be up1

regulated and to have altered temporal expression profiles in the skin of K14Agouti transgenic mice. It is proposed that these gene expression changes
underlie the increased susceptibility of K14-Agouti mice to skin carcinogenesis.
A testable model that synthesizes the data obtained in this study is presented to
explain the mechanism of action of the agouti protein as a tumor promoter in
skin carcinogenesis.

THE MOUSE NONAGOUTI LOCUS
The nonagouti locus (a), which is located on mouse chromosome 2,
regulates the pigmentation pattern in the hairs of mice. The transcript of the
nonagouti locus (referred to as the agouti gene hereafter) is normally expressed
only in the skin and encodes a 131 amino acid (aa) signal peptide. The agouti
protein acts in a paracrine fashion in the microenvironment of hair follicles [1, 2].
In wild-type mice, the agouti protein is secreted from cells of the dermal papillae
during the mid-portion of the hair-growth cycle [3, 4]. Agouti protein competes
with alpha-melanocortin stimulating hormone (α-MSH) for binding to the
melanocortin 1 receptor (MC1R) on the surface of melanocytes [5]. In response to
agouti

signaling

through

MC1R,

melanocytes

switch

from

eumelanin

(black/brown) pigment production to phaeomelanin (yellow/red) pigment
production. As a result of this switch mechanism, individual hairs of wild-type
mice have an agouti pigmentation pattern, which consists of a subapical yellow
band in an otherwise black hair.

An interest in the coat colors of mice can be traced back thousands of
years in China to the first domestication of “fancy mice” that had spontaneous
mutations in various coat-color genes. The mouse fancy gained in popularity
2

during the 1700s and 1800s in Japan and Europe, when mice with a number of
different coat colors were bred as pets. At the beginning of the 20th century, after
the rediscovery of Mendelian genetics in plants, the next question was if the law
of inheritance also applied to the other organisms. Mendelian ratios for the
inheritance of different mouse coat colors were demonstrated by Cuenot in 1902,
who then discovered the first embryonic lethal mutation in mammals through
segregation studies in mice with a completely yellow coat. These mice are now
known to carry a dominant regulatory mutation (lethal yellow, Ay) in the agouti
gene. During this period, the first case of multiple alleles at the agouti gene was
also described by Cuenot [6, 7].

To date, 85 different alleles of the nonagouti locus have been identified, as
reported

in

the

Mouse

Genome

Informatics

(MGI)

database

(http://www.informatics.jax.org). Recessive mutant alleles of the agouti gene
are associated with the underproduction of phaeomelanin, which results in an
increase in the presence of black pigmentation. Dominant mutations in the agouti
gene affect the regulation of wild-type agouti expression, causing high levels of
expression in all tissues of the body. Ectopic over-expression of the wild-type
gene product in all tissues results in yellow-haired mice that are obese, diabetic
and have increased susceptibility to hyperplasia, and spontaneous and
chemically induced tumors ([8, 9], reviewed in [10-19]). Tumor susceptibility has
been observed in a wide variety of tissues including the skin [20, 21], liver [2228], lung [23, 27], mammary gland [22, 23, 29-31] and urinary bladder [32].
Cloning of the agouti gene and identification of its protein product led to
significant advances in characterization of the molecular mechanisms of wildtype mouse coat pigmentation, obesity and diabetes [1, 2, 13, 33]. An historical
perspective on the agouti gene can be found in the review by Wolff in 2003 [12].
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Molecular Characterization of the Agouti Gene
Agouti Gene Structure
In 1992, the agouti gene was cloned by Bultman et al. utilizing the
radiation induced inversion mutation, Is(17; In2)1Gso. The limb deformity (Fmn1,
previously known as ld) and nonagouti (a) loci are normally separated by 22 cM
on mouse chromosome 2. In mice carrying the Is(17;In2)1Gso mutation, an
interstitial inversion in chromosome 2 with breakpoints in a and Fmn1 resulted in
the juxtaposition of Fmn1 and a [34]. Probes for the previously cloned Fmn1 gene
gave molecular access to the a locus, and the cloning and characterization of the
agouti gene and protein structure [1].

Agouti is a seven exon gene, which spans over a 165-kb distance on mouse
chromosome 2 (Fig. 1) [35]. The first four exons of the agouti gene are part of the
5’ untranslated region (UTR). Exons 5, 6 and 7 contain the protein coding
sequences, which are 170 bp, 65 bp, and 385 bp long, respectively [1].

Alternative isoforms of agouti mRNAs contain different combinations of
non-coding exons spliced to the same three coding exons (Fig. 1). Agouti gene
expression is controlled by ventral-specific, and hair-cycle-specific promoters,
which independently regulate the production of solid yellow hairs on the
ventrum, or banded agouti hairs on the dorsum and ventrum, respectively. Two
ventral-specific transcripts contain either exon 1, or exons 1 and 2, spliced to the
three coding exons. These ventral-specific transcripts are expressed throughout
the hair-follicle cycle in the ventrum and produce solid yellow hair coloration.
Two hair-cycle-specific transcripts contain either exon 3 or exon 4 spliced to the
4

Figure 1. Mouse agouti gene structure and alternative transcripts. The agouti gene structure is shown in the top
panel, not drawn to scale. The four non-coding exons (1-4) are represented by parallelograms, and the three coding
exons (5-7) are shown as block arrows. The length of each intron is indicated. Two ventral-specific transcripts
contain either exon 1 (A) or exons 1 and 2 (B) spliced to the three coding exons, and they both specify solid yellow
belly hairs in wild-type agouti mice. Two hair-cycle-specific transcripts contain either exon 3 (C) or exon 4 (D)
spliced to the three coding exons, and they both specify the banded hairs on the dorsum and ventrum of wild-type
agouti mice. Figure adapted from published literature [1, 36-38].

5

A)

B)

C)

D)

6

three coding exons. These hair-cycle-specific transcripts are expressed between
days 2-7 of the hair-follicle cycle in both dorsal and ventral skin and produce the
sub-terminal band of yellow pigmentation in dorsal and ventral hairs [1, 37]. The
regulatory regions of the agouti gene and the manner in which these different
agouti promoters are activated are still unknown [12].

Agouti Protein Structure and Action
The mouse agouti protein is a 131-aa signaling peptide with a molecular
weight of 14,341 Daltons. The agouti protein contains five domains; a signal
sequence, mature N-terminus, basic domain, proline-rich region, and a cysteinerich carboxyl terminus (Fig. 2).
The hydrophobic N-terminus of the agouti protein contains a 22-aa
putative signal sequence, which is essential for in vivo agouti signaling [39]. The
mature N-terminus is 34-aa long and carries a conserved arginine. Glycosylation
of this arginine is required for full biological activity of agouti protein in vivo [40].
The central basic domain (29 aa) has a high proportion of arginine and lysine
residues, and is important for the efficiency of agouti signaling [40, 41]. A
polyproline stretch lies between the basic domain and the cysteine-rich C
terminus. In vitro studies showed that the contribution of the proline-rich region
to agouti protein activity is minimal, and suggested that it might be important in
forming the tertiary structure of the protein by acting as a flexible hinge between
the C-terminus and the N-terminus of the protein [40, 42]. At the C-terminus of
the agouti protein are 10 cysteine residues within the last 40 amino acids, which
form 5 disulfide bonds. This cysteine–rich domain is required for melanocortin
receptor binding, and can antagonize the binding of α-MSH to the melanocortin
receptors in vitro [43, 44].
7

Figure 2. Agouti protein sequence and domain structure. The nonagouti protein has five different domains. The
signal peptide sequence consists of the first 22 amino acids, highlighted in aqua color. The next 34 amino acids,
presented in magenta color, form the mature N-terminus. The basic domain, which is highlighted with green,
contains 29 amino acids. The 6 amino acids highlighted in grey constitute the proline-rich region. The yellow colorcoded area is the cysteine-rich region that has 10 cysteine residues out of a total 40 amino acids. Proline residues
and cysteine residues are shown in green and red color, respectively. Figure adapted from published literature [1,
2].
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Parallel to the changes in gene expression, agouti protein is highly
expressed during the early stage of the hair-follicle cycle, as shown by
immunohistochemistry studies [4]. Agouti protein is localized to the outer root
sheath of the hair follicle and functions in the microenvironment of the hair
follicle [4, 45] in a paracrine fashion [3].

Agouti’s paracrine action was first noted by parabiosis experiments.
Parabiotic union, where two animals are sharing blood circulation, has been used
to study the interrelationships of the endocrine glands between the agouti
mutants, lethal yellow (Ay/a), and their nonagouti (a/a) littermates. Comparison
of the rate of body-weight gain between parabiotic pairs of Ay/a and a/a mice
throughout the experiment showed that there were no effects of parabiosis on
the rate of weight gain of either animal. This observation suggested that agouti
protein acted in a localized manner to induce obesity, and not by entering into
the general circulation [46].

Skin transplantation experiments by Silvers and Russell [45, 47-50]
indicated that the primary site of action of the agouti protein is the follicular
microenvironment, and that the agouti protein acts in a cell non-autonomous
manner. Transplantation of non-pigmented but genetically yellow embryonic
skin to newborn mice with black hair color resulted in intense yellow
pigmentation of hair around the edges of the skin graft, demonstrating that host
melanocytes migrate into the graft follicles and produce pigment according to
the follicular genotype of the graft, independent from their own genotype. In
other words, paracrine action of agouti protein expressed from follicular cells of
graft tissue was regulating the melanogenesis in the host melanocytes.

10

Further research with keratin-agouti-SV40 (KAS) transgenic mice
designed to understand the regulation of pigmentation patterning also
supported the findings of the skin transplantation experiments, showing
paracrine action of agouti protein [3]. In KAS transgenic mice, agouti expression
is directed to basal cells of the epidermis, which are the non-pigmented cells at
the bottom layer of the epidermis that give rise to the epithelial keratinocytes.
Stripes of yellow pigmentation are observed in KAS transgenic mice, which
corresponded to patches of basal epidermal cells expressing agouti. This study
demonstrated the limited radius of agouti protein action, and supported the
previous studies suggesting paracrine action of agouti protein.

Orthologs of the mouse agouti gene have been isolated in different
species, including B. taurus (cattle) [51], C. familiaris (dog) [52], H. sapiens (human)
[53], R. norvegicus (rat) [54], and S. scrofa (pig) [55]. The agouti proteins are highly
conserved in these species. The rat and mouse agouti proteins are 93% identical
at the amino acid level. The pig, dog, human and cattle proteins are 81%, 80%,
78% and 77% identical to the mouse agouti protein, respectively.

Agouti Mutants
Agouti mutant mice exhibit a wide range of coat color phenotypes as a
result of different mutations that impact agouti regulation or protein structure.
All the different alleles of the nonagouti locus represent an intricate dominance
hierarchy of coat color [36, 50, 56, 57]. Hair pigmentation changes from solid
yellow, as observed in mice carrying the most dominant alleles, to solid black in
mice with the most recessive mutations.
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At the top of the dominance hierarchy is the lethal yellow (Ay) allele.
Lethal yellow mice have a regulatory mutation that causes constitutive overexpression of the wild-type agouti gene product in all tissues in heterozygous
animals, including the skin, which results in full yellow coat coloration over all
of the body. Black-and-tan (at) and nonagouti (a) are two examples of recessive
mutations at the nonagouti locus. An insertion in the nonagouti locus in blackand-tan (at/at) mice has a negative impact on expression of the hair-cycle-specific
transcripts that make banded hairs, but does not affect expression of the ventralspecific transcripts that make solid yellow hairs. Therefore, black-and-tan mice
have completely black hair on the dorsum and completely yellow hair on the
ventrum [37]. Nonagouti (a) has a pigmentation pattern that is very close to
being a null mutation. Nonagouti mice are predominantly black, except for small
amounts of phaeomelanin around the pinnae, nipples, and perineum [50]. In
mice carrying the nonagouti allele, an insertion in the locus blocks most all
expression of the hair-cycle-specific and ventral-specific transcripts [1]. At the
bottom of the hierarchical series are mice carrying the extreme nonagouti (ae)
allele, which have a completely black coat color resulting from a complete loss of
agouti function [58].

Dominant Regulatory Mutations of Agouti
Six dominant regulatory mutations — lethal yellow (Ay), viable yellow
(Avy), intracisternal A particle yellow (Aiapy), intermediate yellow (Aiy), sienna
yellow (Asy), and hypervariable yellow (Ahvy) — all exhibit yellow coat coloration
due to continuous action of the agouti protein in the skin.

The lethal yellow (Ay) mutation is the result of a 120-170 kb deletion of the
coding region of the ubiquitously expressed hnRNP associated with lethal
12

yellow (Raly) gene, which places agouti under the regulatory control of the Raly
promoter [9, 59]. Under the transcriptional control of the Raly promoter, the
agouti gene is ubiquitously over-expressed in Ay mutants [8]. Animals
homozygous for the Ay mutation die during embryogenesis due to the deletion
of the Raly gene [9, 59]. Heterozygotes for the Ay mutation have yellow coat
color, and exhibit the pleiotropic effects of obesity, diabetes, and cancer as a
result of the ectopic over-expression of the wild-type agouti protein [8].

The five non-lethal dominant regulatory mutations — Avy, Aiapy, Aiy, Ahvy,
and Asy — are the result of insertions into the non-coding regions of the
nonagouti locus. Expect for Asy, these dominant mutations are caused by
insertions of an intracisternal A particle (IAP) into the locus, which changes the
regulation of agouti expression [60-63]. Regulatory sequences within one of the
long terminal repeats of the IAP elements constitutively activate the agouti gene,
much like the Raly promoter in the Ay allele, and results in ubiquitous overexpression of the agouti protein in all cell types throughout the body. A similar
situation exists for the Asy mutation, wherein a novel element is inserted to the
locus, instead of an IAP.

The pleiotropic effects associated with ubiquitous over-expression of
agouti have been called the ‘Yellow Obese Mouse Syndrome’ [50], where the
main characteristics of the syndrome include yellow coat color, obesity,
hyperinsulinemia, increase somatic growth, and tumor susceptibility (reviewed
in [11, 15, 38, 64]). The full spectrum of the yellow obese mouse syndrome can be
observed in mice carrying the two dominant regulatory mutations Ay and Avy.
Obesity, hyperinsulinemia, and increased somatic growth have also been
demonstrated for mice carrying the mutations Aiy, Asy, Ahvy, and Aiapy. It is highly
likely that mice carrying these mutations also have an increased susceptibility to
13

tumorigenesis, but this has not yet been investigated for these mice. In mice
carrying dominant agouti mutations, increasing levels of agouti expression are
associated with the amount and intensity of phaeomelanin (yellow pigment) in
the coat and with the degree of obesity [63, 65]. Additionally, studies with
transgenic mice that ubiquitously express the normal agouti protein throughout
their body demonstrated that ectopic agouti expression is sufficient to
recapitulate the obesity, diabetes, and yellow coat color phenotypes observed in
mice with these spontaneous dominant agouti mutations [33].

Regulation of Pigmentation by Agouti Signaling
Melanocytes switch from eumelanin to phaeomelanin pigment production
depending on the presence of the α-MSH or agouti proteins within their
follicular environment. α-MSH and agouti compete for the binding of MC1R on
melanocytes with similar levels of affinity (Kd 2.3 nmol/l and Kd 3.7 nmol/l,
respectively) [66, 67]. α-MSH activates adenylyl cylase through MC1R, which
increases cyclic adenosine monophosphate (cAMP) synthesis. This is followed by
an increase in tyrosinase synthesis, which triggers eumelanin pigment
production (reviewed in [12, 68]). Agouti is transiently expressed during the
early stages of each hair-follicle cycle and regulates the switch from eumelanin to
phaeomelanin pigment production. When agouti binds to the MC1R, it displaces
or excludes the binding of α-MSH, and thus prevents adenylyl cylase activation
and cAMP production [5]. In response to reduced cAMP levels, tyrosinase
synthesis decreases and eumelanin pigment production is switched to
phaeomelanin production (reviewed in [12, 68, 69]). Agouti signaling has been
shown to down-regulate transcription of eumelanogenic genes such as
tyrosinase-related protein 1 (Tyrp1), dopachrome tautomerase (Dct), and
14

tyrosinase

(Tyr)

[70,

71].

Additionally,

up-regulation

of

three

genes,

minichromosome maintenance deficient 6 (Mcm6), transcription factor 4 (Tcf4),
and an unknown retinal gene, have been shown during phaeomelanogenesis
[72].

Molecular Mechanisms of Obesity and Diabetes in Yellow
Mice
Ubiquitous over-expression of agouti is responsible for the pleiotropic
effects observed in mice carrying dominant agouti alleles. Confirmation of the
association between agouti protein expression, obesity, and diabetes was first
demonstrated by ectopic expression of the wild-type agouti gene under the
ubiquitously expressed β-actin promoter in transgenic mice [14, 33].

Melanocortin receptors are seven-transmembrane G protein-coupled
receptors (GPCR) that respond to α-MSH and adrenal corticotropic hormone
(ACTH) stimuli [73]. All five members of the melanocortin receptor family
(MC1R through MC5R) differ in their tissue distribution, physiological roles, and
ligand affinity (reviewed in [74, 75]). MC1R is expressed in the skin in
melanocytes and keratinocytes, and regulates coat color pigmentation. It binds to
α-MSH with the highest affinity, which is followed by adrenocorticotropic
hormone (ACTH), and β-MSH. MC2R, which is expressed by the adrenal cortex
and adipocytes, only responds to ACTH, and induces adrenocortical
steroidogenesis [76, 77]. MC3R and MC4R are widely expressed in the brain, and
participate in the hypothalamic regulation of food intake and body weight.
MC4R loss of function is associated with severe early onset obesity in humans.
Both MC3R and MC4R are activated by α-MSH, β-MSH and ACTH, and MC3R
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also binds to γ-MSH (reviewed in [78, 79]). MC5R is ubiquitously expressed in
peripheral tissues and sebaceous glands, and activated by α-MSH, β-MSH, and
ACTH signaling. Recently, MC5R has been shown to act in regulation of exocrine
gland function and human sebocyte differentiation [80].

Ectopic expression of agouti in the brain is primarily responsible for the
obesity and diabetes phenotypes in lethal yellow (Ay) and viable yellow (Avy)
mice. Transgenic studies with Mc3r and Mc4r knockout mice, which exhibit a
similar phenotype to “yellow obese mice” with regard to weight gain and
diabetes, pointed out the possible interaction between central melanocortin
receptors and agouti protein [81, 82]. Pharmacological studies showed that
agouti antagonizes MC3R and MC4R in the brain ([83], reviewed in [79, 84]), as it
does MC1R in the skin of wild-type mice, resulting in altered feeding behavior
and body weight.

Agouti action on adipocytes is also associated with obesity and diabetes,
independent of its action through MC3R and MC4R in the hypothalamus.
Paracrine/autocrine action of agouti in adipose tissue has been suggested to
contribute to the obesity phenotype in yellow mice [13, 85, 86]. Fatty acid binding
protein 4, adipocyte (Fabp4)-agouti transgenic mice, which express agouti only in
adipocytes, had significantly heavier body weights even though the regulation of
food intake by the hypothalamus was intact [87]. Transgenic studies with Fabp4agouti mice demonstrated that agouti regulates adipogenesis, and proliferation
and differentiation of preadipocytes through melanocortin receptors in the
adipose tissue [88]. These findings suggested that weight gain and adipogenesis
are coordinately regulated by melanocortin signaling in the hypothalamus and
adipose tissue [87-90].
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In humans the agouti gene is normally expressed in adipose tissue [53],
and agouti mRNA levels are significantly elevated in adipose tissue of patients
with type 2 diabetes [88]. Agouti signaling in adipose tissue has been shown to
interact with insulin and induce obesity by up-regulating lipogenesis [90], and
agouti synergistically works with insulin to increase fatty acid synthetase (FASN)
activity [91]. Agouti has been shown to increase Fasn mRNA levels through an
agouti responsive element, which is a novel sequence located in the Fasn
promoter region [91]. Additionally, agouti is known to increase leptin (Lep)
expression, synthesis, and secretion in adipose tissue, independent of
melanocortin receptor antagonism [92].

Agouti protein has been shown to increase intracellular calcium levels in
certain cells in vitro, including adipocytes [89, 93, 94]. In both mouse and human
adipocytes, agouti regulates lipogenesis and lipolysis partially through an
intracellular calcium dependent mechanism [85, 95, 96]. Agouti treatment
increases Fasn activity and mRNA levels, and increases triglyceride accumulation
in 3T3-L1 adipocytes, which is inhibited by Ca2+ channel blockade [95].
Treatment of yellow obese Avy/a mice with the calcium channel blocker,
Nifedipine, resulted in significant decrease in fat pad weights and FASN activity
[96].

In adipocytes, in addition to the regulation of Fasn and Lep gene
expression, agouti also directly regulates expression of signal transducer and
activator of transcription 1 (Stat1) and Stat3, and peroxisome proliferator
activated receptor gamma (Pparg) [97].

Increased expression levels of Stat1,

Stat3, and Pparg was first observed in Fabp4-agouti transgenic mice, and similar
increases were observed in 3T3-L1 adipocyte cultures treated with agouti protein
[97]. Agouti has been suggested to regulate Pparg expression through
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melanocortin signaling, as treatment of 3T3-L1 adipocytes with α-MSH has been
shown to block the effects of agouti on Pparg expression [87]. However, the
molecular mechanisms that underlie the regulation of Stat1 and Stat3 by agouti
are still under investigation.

AGOUTI SIGNALING IN TUMOR PROMOTION
The association between the agouti gene and susceptibility to tumor
formation has been recognized since the identification of yellow mice (reviewed
in [10-19]). Recently, transgenic experiments confirmed the role of agouti as a
tumor promoter, and demonstrated that it promotes tumorigenesis in the
absence of obesity and diabetes [98, 99]. In order to understand the context and
significance of current knowledge of agouti signaling during tumor promotion,
background information on the following processes will be presented: two-stage
skin carcinogenesis model, tumor susceptibly in mouse skin, and the increased
susceptibility of mouse skin to tumorigenesis during the anagen stage of the hairfollicle cycle.

Two-Stage Model of Skin Carcinogenesis
Skin cancer is the most common form of cancer in humans. Every year
over one million new patients are diagnosed with skin cancer [100]. Skin acts as a
protective barrier against different environmental conditions, such as ultraviolet
radiation (UV), injury, infectious agents, and chemicals, which are known risk
factors for skin cancer. Although the main risk factor of skin cancer is the
exposure to artificial or natural UV, others factors like human papillomavirus
infections or exposure to chemicals like arsenic can cause development of cancers
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in the skin. Additionally, certain hereditary conditions can increase the tendency
to develop skin cancer [101, 102]. Depending on the underlying cause, different
cell types in the epidermal layer of the skin are affected and the origin of the
tumor cells determines the characteristics of the skin cancer. The most common
form of skin cancer is basal cell carcinoma (BCC), which originates from the
round basal cells located in the lower layer of the epidermis. Melanomas are the
leading cause of death due to skin cancer, and originate from pigment producing
cells, melanocytes. Squamous cells at the upper epidermal layer give rise to
squamous cell carcinomas (SCC). Additionally, precancerous conditions such as
follicular papillomas, actinic keratosis, and Bowen’s disease can turn into
squamous cell carcinomas [103].

Skin cancer can be recapitulated in mice in a two-stage carcinogenesis
model. These experiments on mouse skin have shown that transformation of
normal cells requires at least two separate events, initiation and promotion,
which are then followed by tumor progression [104-109] (Fig. 3).

The first step in tumorigenesis is initiation, which is a single, irreversible,
mutagenic event, and precedes tumor promotion. The polycyclic aromatic
hydrocarbon, 7,12-dimethylbenz[a]anthracene (DMBA), is frequently used as an
initiating agent in skin carcinogenesis experiments. A single application of
DMBA to the skin causes mutations in the Harvey rat sarcoma virus oncogene 1
(Hras1) gene, which is frequently observed in papillomas and SCC [110]. After
initiation with DMBA, promotion of the skin with physical, chemical, or
biological agents is required for clonal expansion of the initiated cell that carries
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Figure 3. Two-stage model of carcinogenesis. Possible outcomes in a two-stage
carcinogenesis experiment. (A) Tumors develop following a one-time initiation
event and repeated exposure of initiated cells to a tumor promoter. Either tumor
initiation (B) or tumor promotion (C) alone is inadequate to induce the
development of tumors.
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a non-lethal mutation. Tumor promoters may be external or internal stimuli.
Repeated exposure of the skin to promoting agents in short intervals results in
altered gene expression and affects cell growth and differentiation of the initiated
cells. During tumor promotion, a continuous mitogenic stimulus provides a
growth advantage to the initiated cells by either increasing resistance to
differentiation or apoptosis or increasing proliferation rates [111]. Promotion is
an essential step for tumor development, which is rate-limiting and reversible;
thus, therapeutic interventions focused on the prevention and regression of
tumor promotion are very likely to be effective [109, 112-114].

The two-stage skin carcinogenesis model has allowed investigators to
explain the complex biological events behind carcinogenesis in simple terms, and
has been an essential tool to study the tumorigenesis process in mice and
humans. Discoveries about tumor initiation and promotion made in two-stage
skin carcinogenesis experiments are also relevant to other tissues [115]. These
experiments are widely used to elucidate the role of chemical carcinogens or
oncogenes, which can be established according to the experimental conditions
required for a carcinogen to drive tumor development (Fig. 3). Tumor initiators
are expected to give rise to skin tumors after a single application of the agent to
the skin of mice, when followed by multiple applications of a tumor promoter to
the skin, such as 12-O-tetradecanoylphorbol-13-acetate (TPA). Likewise, agents
can be tested for their ability to act as tumor promoters by first initiating the skin
with DMBA, followed by repeated applications of the agent in question to the
skin and then monitoring the skin of mice for the development of skin tumors
over time.

Much of our information about tumor development in mice and humans
was based on research using the two-stage skin carcinogenesis model. Following
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advancements in the understanding of skin carcinogenesis, this model has also
been used to study tumor development in other tissues, such as the liver, lung
and breast. Recapitulating these different types of tumors allowed investigators
to understand biological changes associated with different stages of tumor
development.

Tumor Susceptibility in Mouse Skin
Due to the differences in their genetic background, the degree of
susceptibility to tumorigenesis varies between inbred mouse strains [105, 116].
Inherited traits that cause initiation or promotion of the normal cells increase the
susceptibility to tumorigenesis, as cells have already gone through one of the two
essential steps required for tumor development (Fig. 3).

The v-Ha-ras transgenic TG.AC mouse line is one of the examples that
demonstrate the relationship between inherited factors and susceptibility to
carcinogenesis. In this transgenic model, increased susceptibility to skin
carcinogenesis is observed as they carry an activated allele of the Hras1
oncogene, which is a frequently observed mutation in initiated skin cells [117].
SENCAR, sensitivity to cancer, is another well-known mouse model that was
bred for their increased susceptibility to tumor development. SENCAR mice
show high susceptibility to initiation and promotion in two-stage carcinogenesis
experiments, as they require lower doses of carcinogens, and develop higher
numbers of tumors in a shorter time compared to other inbred mice [107, 118].
Although the molecular basis of tumor susceptibility in SENCAR mice is
unknown, involvement of multiple genes has been suggested as different strains
of SENCAR mice show variability in susceptibility to tumorigenesis [112, 119].
The tumor promotion stage has been observed as the key event that determines
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the degree of tumor susceptibility in different inbred mouse strains [116].
Carcinogenesis

studies

with

SENCAR

mice

have

supported

previous

observations, indicating the correlation between the promotion stage and degree
of tumor susceptibility [112].

Inbred mouse strains that demonstrate different degrees of tumor
susceptibility have been utilized for quantitative trait analysis, and currently 17
quantitative trait loci (QTL) have been localized for tumor susceptibility in skin:
skin tumor susceptibility (Skts1 through Skts13) (reviewed in [120]), and
promotion susceptibility (Psl1 through Psl4) loci [121, 122]. Identification of new
genetic mechanisms that impact tumor susceptibility will be facilitated by
cloning and characterizing the genes associated with these QTLs.

Hair-Follicle Cycle and Tumor Susceptibility
The hair follicle (HF) is a regenerating structure that resides in the dermal
layer of the skin (Fig. 4). All mature hair follicles proceed through cyclical
changes throughout the life of mammals, which can be categorized into four
phases; growth (anagen), regression (catagen), relative resting (telogen), and
shedding (exogen). Hair follicles exhibit distinct morphological characteristics at
each stage, which is helpful for identification and dissection of anagen, catagen,
and telogen stages [123].

The most recognizable structure of the HF is the hair bulb, which is an
onion shaped structure formed by relatively undifferentiated matrix cells and HF
melanocytes. The dermal papilla (DP) consists of differentiated mesenchymal
cells, and resides adjacent to the hair bulb at the base of the HF, which is later
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Figure 4. Structure of the hair follicle and the hair-follicle cycle stages.
Morphological changes associated with different hair-follicle cycle stages are
presented. The stages of the hair-follicle cycle are anagen (growth), catagen
(regression), and telogen (resting). The structures of an anagen hair follicle are
shown: hair shaft (HS), sebaceous gland (SG), inner root sheath (IRS), outer root
sheath (ORS), matrix (MX), and dermal papilla (DP). The hair follicle exhibits
distinctive morphology associated with each stage (see text for details). Figure
adapted from published literature [123].
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surrounded by the hair bulb during the anagen stage of the hair-follicle cycle.
DP cells orchestrate hair follicle formation during embryogenesis, and the hair
bulb continues to be an important structure during hair-follicle cycling and in
hair formation in postnatal life. Matrix cells (MX) of the hair bulb differentiate
into the hair shaft (HS) and inner root sheath (IRS), which surrounds the HS. The
outer root sheath (ORS) consists of HF keratinocytes, which form the outermost
layer of the HF, merging the basal layer of the epidermis and the HF. The bulge
region is a specialized part of the ORS located at the insertion site of the arrector
pili muscle (APM), which contains stem cells that give rise to both the HF and
interfollicular keratinocytes.

Anagen is the stage of active growth, when the hair follicle proliferates
and differentiates to produce a new hair shaft. The first set of changes marking
the start of anagen is the enlargement and repositioning of the DP inside the hair
bulb. After receiving initiation signals from the hair matrix, DP cells signal back
to the MX, instructing the matrix cells to differentiate and proliferate to form a
new hair shaft. During anagen, melanin pigment is synthesized by hair follicle
melanocytes. The hair follicle, which is located in the dermis, elongates and
crosses the dermis-subcutis border, growing deep into the subcutis. Additionally,
epidermal and dermal layers of the skin thicken to accommodate the growing
hair follicle [124-127].

Apoptotic events control the regression of the hair follicle throughout the
catagen stage, which is a transitional stage between anagen and telogen. During
catagen, the DP condenses and resumes its ball-shape, while the hair bulb
retracts back toward the dermis, leaving the DP outside of the bulb. As the HF
gets shorter, all the HF structures move back into the dermis leaving behind a
membrane trail. At the end of catagen, the hair follicle reaches its smallest size
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before entering into the next resting period [124-127]. By the start of telogen,
molecular pathways that have regulated the changes during anagen and catagen
turn back to their basal activity levels. Throughout telogen, the hair follicle
preserves its size and shape, and the hair shaft stays attached to the follicle until
it is shed or pushed out by the new hair produced during the following anagen
stage [124-127].
Initiation of the hair-follicle cycle, progression through each of the stages,
and the transitions from one stage to the next requires the involvement of
different signaling pathways communicating mostly between matrix cells of the
hair bulb and the DP. These molecular controls and changes associated with each
stage of the hair-follicle cycle are less clear than the associated morphological
changes.

Many

signaling

pathways

that

are

important

in

embryonic

development, such as hedgehog, patched, Wnt, dishevelled, armadillo,
engrailed, and Notch are critical for normal hair follicle morphogenesis [124],
and also regulate postnatal hair follicle growth and cycling processes [127]. For
instance, transient expression of sonic hedgehog signaling (Shh) is required for
the embryonic development of the hair follicle, and it also acts as a biological
switch initiating the anagen stage in cycling postnatal follicles [128].
Additionally, estrogens, thyroid hormones, glucocorticoids, retinoids, and
growth hormones modulate hair growth [124], and many genes, including a,
Pdgfa, Stat3, and Prl act as molecular mediators of hair follicle growth [126].
Integration of bone morphogenetic protein (Bmp) and Wnt signaling pathways
has been suggested to regulate hair follicle stem cell differentiation and
proliferation [129], along with other recently identified regulators, such as
telomerase reverse transcriptase (Tert) [130, 131] and RAS-related C3 botulinum
substrate 1 (Rac1) [132]. The molecular mechanisms that control hair follicle
morphogenesis and cycling have been shown to be involved in the regulation of
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embryonic and postnatal development of other tissues, such as teeth, feathers,
and mammary glands [133], and are suggested to have a role in other
developmental systems [127]. Details of the molecular mechanisms underlying
the hair-follicle cycle and its regulation have been reviewed by Stenn and Paus
[126, 134].

The first two hair-growth cycles (catagen, telogen, anagen) after birth are
completed precisely in 12 weeks. The first catagen stage takes place during the
first two weeks of life, followed by the first telogen and anagen stages, which are
completed in three and a half weeks after birth. The second postnatal hair-follicle
cycle takes twice as much time to complete, and occurs during the second and
third months after birth. All postnatal hair follicles go through the first and
second hair-follicle cycles in a synchronized manner. After the second anagen
stage this synchronization is lost and each hair follicle starts to cycle independent
from one another, so in one skin section follicles in all different hair-follicle cycle
stages can be observed [125]. In adult mice, the hair-follicle cycle can also be
synchronized under defined experimental conditions. If hair shafts are removed
by hot wax application during the second telogen stage, at around 7 to 8 weeks
of life, the second anagen stage will be initiated at the same time for all the hair
follicles in the epilated area. As all the hair follicles are induced to initiate anagen
at the same time immediately following epilation, they progress synchronously
through the next anagen, catagen and telogen stages. Synchronization of the hairfollicle cycle allows one to study histological and molecular changes during each
specific stage of the hair cycle [135].

Besides hair shaft formation, the hair-follicle cycle is important at the
cellular level as it impacts different molecular events, such as cell-cell
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communication, tissue regeneration, aging, and carcinogenesis (reviewed in
[126]).
Different cell types of the hair follicle give rise to morphologically distinct
tumors, and an association between different types of tumors and specific stages
of the hair-follicle cycle has been known for many decades [136-138]. A
systematic study was conducted in which the histology of various types of hairfollicle tumors was correlated with the stage of the hair-follicle cycle when
tumors arose [131]. This study demonstrated that tumors that arise in anagen
originate from the hair MX, ORS and IRS of the hair follicle, which form the hair
shaft of the mature anagen follicle [139]. Additionally, it has been demonstrated
that a majority (88%) of hair-follicle tumors develop during the anagen phase
from the fully differentiated follicular cells [139]. Skin papillomas have been
shown to originate from hair follicle structures in v-Ha-ras transgenic TG.AC
mice after initiation of the anagen stage [140]. Two-stage carcinogenesis
experiments demonstrated that the sensitivity of the skin to tumor formation is
greatest during the anagen stage of the hair-follicle cycle [137, 141]. Both Swiss
and SENCAR mice developed higher numbers of tumors at the end of the 40week period following initiation by DMBA during the early anagen stage of the
hair-follicle cycle.

These observations have been supported by the demonstration of the
transient proliferation of follicular epithelial stem cells during early anagen [142].
All stem cells are especially susceptible to tumorigenesis due to their potential
for proliferation and their long-term presence in tissues, which allow for the
accumulation of multiple oncogenic events in one cell. Follicular epithelial stem
cells located in the bulge region of the ORS give rise to both the hair shaft and
epidermis (reviewed in [143, 144]), where the skin papillomas and other anagen
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tumors have been shown to originate. It has been suggested that stimulation of
follicular epithelial stem cells by the initiation of the anagen stage is responsible
for increased susceptibility to tumorigenesis in mouse skin during the anagen
stage of the hair-follicle cycle [142].

Agouti is a Tumor Promoter
Even though many aspects of the molecular mechanisms of agoutiinduced obesity and diabetes have been explained, virtually nothing is known
about the molecular basis of agouti-induced tumor susceptibility in yellow mice.

The dominant agouti mutations Ay and Avy influence tumor development
by shortening the latency period (time from initial exposure to first detection) of
tumor formation [28, 38] and increasing the prevalence of tumors (number of
animals effected) [15, 26, 27, 98, 99]. While these typical effects of Ay and Avy
mutations are observed in many tissues, several studies have revealed
contradictory findings. First, there was no change in the latency period of
chemically induced thymic lymphomas observed in mice carrying either the Ay
or Avy mutations [145]. Additionally, a decreased prevalence of spontaneous
teratomas [146] and mammary tumors have been reported in mice carrying Ay.
Despite the decrease in number of animals with mammary tumors, the latency
period needed for development of mammary tumors in Ay mice was still shorter
[147]. There are also contradictory findings on the in vitro transformation of
fibroblasts from Avy mice. A decreased prevalence of spontaneous and
chemically-induced transformation of primary fibroblasts from an Avy/a mouse
was observed [148], whereas established cell lines from Avy/a fibroblasts showed
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an increased prevalence during spontaneous focus formation experiments
compared to a/a control cell lines [149].

To date, many different mechanisms have been proposed to explain the
role of agouti in increasing tumor susceptibility in mice, including increased
proliferation of transformed cells, increased DNA and protein synthesis,
increased mitosis in sensitive tissues, and metabolic changes in precancerous
cells [15, 16, 38], but the role of agouti in tumor susceptibility remains largely
unknown.

The first demonstration that agouti may have a role in tumor promotion
independent of its effects on obesity and diabetes came from a study in Avy/a
mice. Depending on the methylation level of regulatory elements of the IAP
insertion in the Avy allele, Avy/a mice show different levels of agouti expression
and different degrees of obesity and diabetes. High levels of IAP methylation
result in extremely low levels of ubiquitous agouti expression in Avy/a mice.
These mice have normal body weights and normal blood glucose levels, but they
have a subtle alteration in coat color (slight increase in size of sub-terminal
yellow band) that is called pseudoagouti. Low levels of IAP methylation result in
high levels of ubiquitous agouti expression in Avy/a mice. These mice are obese,
diabetic, and have a solid yellow coat color. Obese yellow Avy/a mice, lean
pseudoagouti Avy/a mice, and lean black nonagouti a/a control mice were fed a
diet containing lindane (gamma-hexachlorocyclohexane) for 24 months [27]. In
response to lindane feeding, lean pseudoagouti Avy/a mice had a higher
prevalence of lung tumors, and hepatocellular adenoma and carcinoma than lean
a/a control mice, whereas the obese yellow Avy/a mice had the highest prevelance
in all cases. It is unclear if the higher number of obese yellow Avy/a mice with
tumors compared to lean pseudoagouti Avy/a mice was caused by metabolic
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effects associated with obesity and diabetes, or to higher levels of ubiquitous
agouti expression in the yellow mice. Importantly, the greater tumorigenic
response of lean pseudoagouti Avy/a mice compared to lean nonagouti a/a mice
demonstrated that obesity and tumor susceptibility are independent effects of
ectopic agouti expression [27].

A transgenic study in which the albumin promoter was used to direct the
expression of the wild-type agouti cDNA to the liver demonstrated that agouti is
a tumor promoter in the liver independent of its effects on obesity and diabetes.
Albumin (Alb1)-agouti transgenic mice, in which agouti protein is ectopically
expressed only in the liver, have normal body weight and normal levels of
plasma insulin and blood glucose [98]. Diethylnitrosamine (DEN) is a mutagenic
agent frequently used for the initiation of liver cells. A single intraperitoneal
injection of DEN in alb-agouti transgenic mice and non-transgenic control mice
resulted in an increased number of tumors that developed in the livers of the
transgenic mice compared to controls. This single initiation event with a
hepatocellular carcinogen was sufficient to lead to a significantly greater number
of liver tumors in transgenic mice following continuous exposure of the initiated
liver cells to high levels of agouti signaling. These findings demonstrated that
agouti acts as a tumor promoter in a two-stage carcinogenesis experiment, and
its tumor promoting action is independent from the obesity and diabetes
phenotypes [98, 99].

A second transgenic study had the goal of extending these findings and
defining more precisely the role of agouti in carcinogenesis. For this purpose,
transgenic mice expressing the agouti gene in the skin under the regulatory
control of the keratin complex 1, acidic, gene 14 (Krt1-14, abbreviated as K14)
promoter were used in classical two-stage skin carcinogenesis experiments. K1431

Agouti mice over-express the agouti gene in the skin in a constitutive manner,
resulting in continuous antagonism of MC1R throughout the hair-follicle cycle
and in mice with a solid yellow coat color. The K14-Agouti transgene is
expressed in the basal layer of the epidermis and outer root sheath of the hair
follicle. Similar to the liver-specific transgenic mice, K14-Agouti transgenic mice
are not obese or diabetic, again demonstrating that agouti acts in a paracrine
fashion within a few cell distances from its point of secretion, and not by entering
into the general circulation [150] (Fig. 5).

K14-Agouti transgenic mice were used in a classical two-stage skin
carcinogenesis experiment designed to determine if agouti acts as a tumor
promoter in the skin independent of obesity and diabetes [99]. Two groups of
transgenic and control mice were treated with either the tumor initiator DMBA,
or the tumor promoter TPA, and the number of skin papillomas that developed
in transgenic and control mice was determined for 52 weeks. In the first group,
where the skin of transgenic and control mice was only initiated by a single
topical application of DMBA, the number of mice with skin papillomas and the
number of papillomas per mouse were significantly greater in the transgenic
mice. These data showed that a high level of agouti protein was able to promote
the development of skin tumors following initiation, independent from the
obesity and diabetes phenotypes. In the second group, both transgenic and
control mice were only promoted with repeated administration of the tumor
promoter TPA, without any initiation. Neither the K14-Agouti transgenic mice
nor the controls developed any papillomas during the 52 week period, indicating
that agouti was not acting as an initiator, and that tumors do not arise
spontaneously in K14-Agouti mice in the absence of initiation.
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Figure 5. K14-Agouti transgenic and non-transgenic control mice. (A, B)
Constitutive agouti signaling in the skin of K14-Agouti transgenic mice causes
the mice to have a solid yellow coat color compared to their nonagouti (black)
littermate controls. Transgenic mice are not obese or diabetic.
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In the same study, a third group of K14-Agouti transgenic and control
mice were initiated with DMBA, which was then followed by TPA promotion.
As expected, the control mice developed papillomas under these experimental
conditions. In transgenic mice, K14-Agouti expression acted synergistically with
the chemical tumor promoter, TPA, to increase the cumulative prevalence,
multiplicity, and malignant conversion rate of tumors, and to decrease the latent
period of tumor formation compared to control mice [99]. These two-stage
carcinogenesis experiments with both alb-Agouti and K14-Agouti transgenic
mice showed that agouti acts as a tumor promoter in the liver and skin,
respectively, in the absence of the obesity and diabetes phenotypes.

Although it has been clearly established that the agouti protein acts as a
tumor promoter, the mechanism of action of agouti protein in tumor promotion
is still unknown. We speculated that the constant presence of high levels of
agouti protein (a paracrine signaling molecule) in the skin of K14-Agouti mice is
the promoting force in these mice. As discussed above, the paracrine/autocrine
action of agouti in the hypothalamus (in spontaneous dominant agouti mutants)
and adipose tissue (in Fabp4-Agouti transgenic mice) was previously shown to
be responsible for the obesity and diabetes phenotypes, rather than any systemic
action of agouti protein. Additionally, agouti is known to directly regulate the
expression of several genes functioning in pigmentation, lipogenesis, and
adipocyte metabolism.

In this research, the main goal was to extend these findings and to address
the following fundamental issues regarding agouti and skin carcinogenesis:

a) Identify the changes in gene expression patterns in the skin of K14Agouti transgenic mice using cDNA microarray and real-time quantitative
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reverse transcriptase – polymerase chain reaction (qRT-PCR) analyses in
order to identify molecular pathways associated with the promotion of
skin carcinogenesis by the agouti protein.

b) Determine if the over-expression of agouti in the skin of K14-Agouti
transgenic mice is affecting the regulation and progression of the hairfollicle cycle.

c) Investigate if changes in gene expression profiles in the skins of the
transgenic mice are associated with specific stages in the hair-follicle cycle.

The agouti protein acts as a tumor promoter in the skin of K14-Agouti
mice, as evidenced by the fact that skin tumors develop only following chemical
initiation. In the untreated skin of K14-Agouti mice there is ongoing promotion
due to the over-expression of agouti protein in the skin, but these mice do not
develop skin tumors in the absence of initiation. Therefore, any gene expression
changes detected in the untreated skin of K14-Agouti mice may be associated
with the tumor promotion stage of skin carcinogenesis, and provide insight into
the genetic pathways through which the agouti protein may be functioning in
skin cancer. Differentially expressed genes in the skin of K14-Agouti transgenic
mice are identified by microarray analysis, and the results of microarray analysis
are validated and extended with qRT-PCR analysis.

Gene expression analysis using microarray technology can determine
differential expression levels of thousands of genes simultaneously in a highthroughput fashion. Microarray analysis has been a valuable tool for identifying
changes in the expression of genes under different experimental circumstances,
such as following a genetic alteration, during different stages of disease, or in
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response to various treatments. The identification of split hand/foot
malformation (ectrodactyly) type 1 (Shfm1) as a TPA responsive gene expressed
in keratinocytes by microarray analysis is only one of many examples of the
application of the microarray technique for novel gene discovery [151].
Additionally, microarray analysis can be utilized for establishing molecular
signatures associated with different disease states for the purpose of diagnosis
and for predicting disease outcome [152, 153]. In cancer research, microarraybased techniques have been used in a wide range of applications, such as to
identify biomarkers associated with different cancer stages, responses to therapy,
and disease prognosis. In a recent study, microarray analysis was used to
identify differentially expressed genes in mouse squamous skin cancer induced
by DMBA and TPA treatment. Differential expression of four genes — annexin
A1 (Anxa1), lipocalin 2 (Lcn2), S100 calcium binding protein A8 (calgranulin A)
(S100a8), and serine/threonine kinase 38 like (Stk38l) — identified in mice were
also shown to be differentially expressed in human skin tumor samples,
demonstrating the strength of microarray analysis for the identification of novel
cancer related genes [154].

In the following chapter, the design and results of this study are
presented. The non-initiated skins of K14-Agouti and control mice were
examined by cDNA microarray analysis, resulting in the identification of 181
genes that had significantly different expression levels in K14-Agouti mice
compared to control mice. These gene expression changes are associated with the
promotion stage of skin carcinogenesis in K14-Agouti mice. Constitutive
signaling by agouti protein in the skin of K14-Agouti mice, independent of any
effects of K14-Agouti on skin morphology or on timing of hair-follicle stages,
caused these gene expression differences. Additionally, qRT-PCR analysis
demonstrated that the levels and temporal patterns of expression of 10 genes
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previously associated with skin and/or other epithelial cancers were
significantly altered in the skin of K14-Agouti transgenic mice. Agouti-induced
over-expression of these proto-oncogenes in the skin of K14-Agouti mice is
proposed to be associated with their increased susceptibility to skin
carcinogenesis.

In the last chapter, the results obtained from the microarray and qRT-PCR
experiments are integrated into a hypothetical model to explain the mechanism
of action of the agouti protein as a tumor promoter in skin carcinogenesis.
Finally, strategies for future follow-on experiments to further investigate the role
of agouti in tumor promotion and to test aspects of the proposed model are
presented.

37

CHAPTER II
DIFFERENTIAL EXPRESSION OF SKIN
CANCER AND HAIR-FOLLICLE CYCLE
REGULATED GENES IN TUMOR
SUSCEPTIBLE K14-AGOUTI MICE
This chapter is a slightly revised version of a paper by the same title,
which is ready for submission by Yesim Aydin-Son and Edward J. Michaud.

My use of “we” in this chapter refers to my co-author and myself. My
primary contributions to this paper include: (1) identification, optimization and
application of the experimental approaches, (2) some of the mouse husbandry,
(3) tissue collections from mice, (4) most of the RNA isolation and cDNA
preparation, (4) microarray experiments and analysis, and data mining, (5) most
of the real-time qRT-PCR experiments, (6) interpretation of the qRT-PCR data, (7)
hair-cycle synchronization experiments, (8) histological staging of the hair-follicle
cycle, (9) most of the gathering and interpretation of literature, and (10) writing
the manuscript.
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INTRODUCTION
The mouse nonagouti (a) gene, hereafter referred to as agouti, encodes a
paracrine-acting signaling molecule in the skin that regulates coat-color
pigmentation [1, 2]. The agouti gene is expressed in the dermal papilla of hair
follicles in a transient manner only during the early anagen (growth) stage of the
hair-follicle cycle, when hair follicles proliferate and differentiate [3, 4]. Agouti
signaling causes hair-follicle melanocytes to switch from black to yellow pigment
production by signaling through the melanocortin 1 receptor (MC1R) [5]. As a
result of this switch mechanism, individual hairs of wild-type mice have an
agouti pigmentation pattern, which is black with a sub-apical yellow band [155].
Importantly, the skin of mice is also more susceptible to carcinogenesis during
the anagen stage of the hair-follicle cycle [139, 141, 143], a time when many
signaling pathways are normally activated in hair follicles (reviewed in [156158]).

Dominant regulatory mutations in the mouse agouti gene, such as lethal
yellow (Ay) and viable yellow (Avy), cause ectopic over-expression of the wildtype gene product in every tissue of the body [1, 2, 59]. This alteration in agouti
expression results in yellow-haired mice that are obese, diabetic and have
increased susceptibility to hyperplasia, and spontaneous and chemically induced
neoplasia [8, 9] (reviewed in [11, 16, 17]) in a wide variety of tissues (e.g., skin
[20, 21], liver [22-28], lung [23, 27], mammary gland [22, 23, 29-31], and urinary
bladder [32]).

Liver-specific expression of the agouti gene in transgenic mice was shown
to promote hepatocellular carcinogenesis, even in the absence of obesity and
diabetes [98]. We recently extended these findings to show that expression of the
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agouti gene in the skin of transgenic mice also promotes skin cancer in the
absence of obesity and diabetes [99]. In K14-Agouti transgenic mice, the wildtype agouti gene is over-expressed in the skin under the regulatory control of the
keratin complex 1, acidic, gene 14 (Krt1-14, abbreviated as K14) promoter. These
transgenic mice have yellow hair as a result of continuous agouti antagonism of
MC1R on melanocytes, but do not exhibit the obesity or diabetes phenotypes
observed in mice carrying the Ay or Avy mutations [150]. The obesity and diabetes
phenotype exhibited by mice harboring the Ay and Avy mutations is likely caused
by over-expression of agouti in the brain and antagonism of MC4R [83]. In twostage skin carcinogenesis experiments with K14-Agouti transgenic mice, the
agouti protein was shown to act as a tumor promoter since it promoted the
development of skin tumors only after the skin was initiated with a single subcarcinogenic dose of 7,12-dimethylbenz[a]anthracene (DMBA) [99]. Although
agouti has been shown to promote the development of hyperplasia and
neoplasia in numerous tissues, the mechanism of action of agouti protein in
tumor promotion remains largely uncharacterized [12].

Our hypothesis for the role of the agouti protein in tumor promotion is
that agouti may be inducing the up-regulation of proto-oncogenes as a
consequence of high levels of constitutive paracrine signaling of cells and
pathways that may or may not normally encounter agouti protein. As a first step
to test this possibility, we used cDNA microarray and real-time qRT-PCR
analyses in order to examine gene expression levels in the skin of non-initiated
K14-Agouti transgenic mice compared to non-transgenic littermate control mice.
Our goal was to identify changes in K14-Agouti skin at the molecular level due
to over-expression of the agouti gene in the skin, which in turn could be
associated with tumor promotion following spontaneous or chemical initiation.
We identified a set of genes that are significantly up-regulated in the skin of K1440

Agouti mice and that have previously been shown to play a role in skin, and
epithelial cancer biology.

MATERIAL and METHODS
Mice
Mice of the transgenic line TG2579K14iA [150] were backcrossed to
C57BL/6J mice for more than 10 generations in order to obtain transgenic mice
that are congenic on the C57BL/6J genetic background, which are hereafter
referred to as K14-Agouti transgenic mice. K14-Agouti transgenic mice are
hemizygous for the transgene and are non-agouti (a/a) at the endogenous agouti
locus, as determined by Southern blot analysis [1]. C57BL/6J (a/a) littermates
were used as controls for K14-Agouti transgenic mice. All mice were maintained
in the Mammalian Genetics Research Facility, Oak Ridge National Laboratory,
Oak Ridge, TN, and all experiments involving mice were conducted under
approved Institutional Animal Care and Use Committee protocols.

RNA Isolation and cDNA Preparation
Dorsal skin sections from adult male K14-Agouti transgenic mice and a/a
control mice were dissected and snap-frozen in liquid nitrogen. Total RNA was
isolated using TRIzol (Invitrogen), followed by on-column DNAse treatment and
a purification step with the Qiagen RNeasy Mini Kit. SuperScript II Reverse
Transcriptase (Invitrogen Life Technologies) was used to generate cDNA
according to the manufacturer’s instructions.
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Microarray Analysis
Ontario Cancer Institute cDNA microarrays (OCI, Toronto, Canada)
containing the NIA/NIH 15K mouse EST clone set [159] were used for
microarray experiments. Labeling and hybridization of cDNAs were performed
by following the TIGR Protocol for indirect amino-allyl labeling of cDNAs [160].
An

optimized

version

of

this

protocol

is

available

at

http://web.utk.edu/~saydin/protocols. Three biological replicates were used to
minimize experimental and individual variations. Total RNA from three
different eight-week-old male K14-Agouti transgenic mice was hybridized
individually against a pooled total RNA sample from three sex-matched, agematched non-agouti control mice. All three hybridizations were repeated with
dye swapping to minimize dye bias in the microarray analysis. Since each one of
the NIA 15K mouse ESTs is spotted in duplicate on the microarray slides, 12 data
points were generated for the expression level of each gene, which were
combined for statistical analysis. Fluorescence intensities were measured using
ScanArray (GSI Lumonics), and Imagene 5.2 (BioDiscovery) was used for image
acquisition and quantification. Composite images were generated by Imagene
software.

Statistical Analysis
BRB-ArrayTools developed by Dr. Richard Simon and Amy Peng Lam,
and SAM (significance analysis of microarrays) [161] software packages were
used for the statistical analysis of gene expression data. After local background
correction with Imagene 5.2 output, average log (base 2) intensities were used for
normalization. Each dye-swap experiment was individually normalized with
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LOWESS analysis using BRB-ArrayTools software. Statistical significance of
alterations in gene expression levels between transgenic and control mice were
determined by SAM. Threshold values (delta) were selected by considering the
total number of genes on the array, the number of genes found significantly
different at that threshold value, and the False Discovery Rate (FDR) for the
threshold.

Real-Time qRT-PCR
The qRT-PCR method depends on the real-time measurement of PCR
products amplified in every cycle, which is proportional to the amount of
starting template [162-164]. We used the Cepheid SmartCycler real-time PCR
machine for the qRT-PCR experiments. The TaqMan primers and probes were
purchased from Applied Biosystems (TaqMan Assays-on-Demand Products
Assay

numbers:

Mm00515219_s1,

Mm00438337_m1,
Mm00448100_m1,

Mm00476174_m1,

Mm00516876_m1,

Mm00435540_m1,

Mm00440911_m1,

Mm00439518_m1, Mm00456961_m1, Mm00436931_m1). The 18S RNA (Rn18s)
gene was used as an internal control to normalize experimental data. The
threshold cycle (CT) for all experimental genes was first normalized to the
corresponding Rn18s CT. Relative fold differences were then determined using
the 2

–∆∆CT

method [165] by comparing each experimental sample to the control

sample.

Synchronization of Hair-Follicle Cycle
To repeat the qRT-PCR experiments on skin samples in which the exact
stage of the hair-follicle cycle was determined by diagnostic histology, we
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synchronized the hair-follicle cycle on the dorsal skin of eight-week-old female
K14-Agouti transgenic and control mice by wax epilation, as described
previously [166]. Mice were euthanized at eight time points (0, 3, 5, 8, 12, 17, 20
and 25 days) after wax epilation. Two transgenic and two control mice were
analyzed at each time point, and the expression level of each gene was
measured in duplicate for each mouse.

Histology
The samples of dorsal skin were fixed with Fekete’s acid-alcoholformalin, and embedded in paraffin blocks. Sections were stained with
hematoxylin and eosin, and Giemsa. Slides were examined under routine light
microscopy (Zeiss Axioskop2), and hair-follicle cycle stages were determined
by following the guideline for the classification of murine hair follicles in
distinct hair-cycle stages [123].

RESULTS
Microarray Analysis of Gene Expression in the Skin of
Adult K14-Agouti and Control Mice
Changes in gene expression levels in the skin of non-initiated K14-Agouti
mice were identified using 15K Toronto cDNA microarrays. BRB-ArrayTools and
SAM software programs were used for the analysis of microarray data. We used
self-to-self hybridization of control samples (data not shown) for quality
assurance of the microarray technique and the statistical analysis of data. Data
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generated from six different hybridization experiments of skin RNA from eightweek-old transgenic and control male mice were used collectively to identify
genes with significantly different expression levels in K14-Agouti mice (Fig. 6).
Microarray analysis resulted in the identification of 63 ESTs that were upregulated (Table A-1 in Appendix) and 118 ESTs that were down-regulated
(Table A-2 in Appendix) in the skin of K14-Agouti mice compared to the control
mice at the delta threshold value of 0.4 with a FDR of 22% (see Materials and
Methods). The complete data set was deposited in NCBI’s Gene Expression
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and is accessible through
GEO Series accession number GSE4641 [167].

The identities of all 63 significantly up-regulated and an equal number of
significantly down-regulated EST clones were determined using the NCBI Entrez
Gene database [168]. Among the top 63 EST clones in both groups, only 40 upregulated clones (Table 1) and 29 down-regulated clones (Table 2) were
associated with known genes with previously determined biological functions.

qRT-PCR Analysis of the Temporal Expression Profiles of
10 Genes in the Skin of K14-Agouti and Control Mice
Since the microarray data were from the skin of mice at a single age, we
next selected a subset of these genes, and others, for analysis of their temporal
expression patterns using qRT-PCR. We selected four up-regulated genes from
the microarray results (casein kinase II, alpha 2, polypeptide, Csnk2a2; Harvey rat
sarcoma virus oncogene 1, Hras1; platelet derived growth factor, alpha, Pdgfa;
and plasminogen activator, urokinase receptor, Plaur) that have known functions
associated with skin cancer biology, cellular differentiation, cellular proliferation,
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Figure 6. Identification of significantly altered gene expression levels in the skin
of K14-Agouti transgenic mice. Data generated from six independent microarray
hybridization experiments with skin RNA from transgenic and control mice on
cDNA microarrays were analyzed by SAM software as described in Materials
and Methods. A scatter plot of the observed relative difference d(i) versus the
expected relative difference dE(i) is shown. Solid line indicates no differential
expression. Dashed lines mark the cutoff value for significant differential
expression when the threshold value (delta) was 0.4 and the FDR was 22%. This
analysis identified 181 significantly altered genes in K14-Agouti mice compared
to non-transgenic control mice, which are plotted outside of the dashed lines.
Out of 15,264 mouse ESTs, 63 genes were up-regulated (in red, upper-right of
plot) while 118 genes were down-regulated (in green, lower-left of plot).
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Table 1. List of 40 genes with known biological functions that are significantly upregulated in the skin of K14-Agouti mice. Shown for each gene are the GeneID
number, gene symbol, gene name, score (d), and fold difference of gene expression
in K14-Agouti skin compared to controls. Genes are sorted based on score (d), or d
(i), which is assigned by the SAM program according to the change in gene
expression relative to the standard deviation of repeated measurements. Four
genes selected for further analysis are marked by double borders.
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Table 2. List of 29 genes with known biological functions that are significantly
down-regulated in the skin of K14-Agouti mice. Shown for each gene is the
GeneID number, gene symbol, gene name, score (d), and fold difference of gene
expression in K14-Agouti skin compared to controls. Genes are sorted based on
score (d), or d (i), which is assigned by the SAM program according to the
change in gene expression relative to the standard deviation of repeated
measurements.
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and/or hair-follicle cycle events. Additionally, we included two markers of
cellular proliferation (proliferating cell nuclear antigen, Pcna; and telomerase
reverse transcriptase, Tert), two markers of keratinocyte differentiation (Krt1-14
and involucrin, Ivl), and two transcription factors (signal transducer and
activator of transcription 1, Stat1; and signal transducer and activator of
transcription 3, Stat3) previously shown to be up-regulated by ectopic agouti
expression in adipose tissue [97]. Each of these 10 genes has been associated with
skin cancer and/or other epithelial cancers (Table 3). The expression profiles of
these genes were examined in transgenic and control mice ranging in age from
4.5 to 26.5 weeks (Table 4).

The data in Table 4 demonstrated that all 10 genes were up-regulated in
the skin of K14-Agouti mice compared to control mice, but not at all ages. To
better understand the impact of K14-Agouti transgene expression on the
expression patterns of these 10 genes, we next examined their wild-type
temporal expression profiles in control mice (Fig. 7A and B). For this analysis, the
expression level of each gene in the skin of 4.5-week-old control mice was
assigned the value of 1.0 and the expression levels of each gene at all later ages
were reported relative to this level. This analysis revealed that the wild-type
expression profiles of these genes exhibited two general patterns. In Group I
genes (Hras1, Krt1-14, Ivl, Pdgfa, Plaur, Stat1, and Stat3), expression remained at a
baseline level from about 4.5-11.4 weeks of age, followed by up-regulation at
later ages (Fig. 7A). The hair follicles of mice develop postnatally in a
synchronous manner through two cycles of regression (catagen), resting
(telogen), and growth (anagen), up until they are about 12 weeks old. After this
time, hair follicles continue to cycle but in an asynchronous manner relative to
each other [123]. The first catagen and telogen stages occur prior to 4.5 weeks of
age, which is the youngest age of mice in which we examined gene expression
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Table 3. Summary of known functions of 10 genes with altered temporal expression patterns in the skin of K14Agouti mice
Gene
Symbol

Role in Epithelial and/or Skin Cancer Biology

Expression and Role During the Hair-Follicle Cycle

Csnk2a2

Transformation of mammary epithelium due to altered expression
[169].

Acts in casein kinase signal transduction pathway in
keratinocytes [170].

Hras1

Activating point mutations are present in 30% of all human
tumors; 10-20% of SCC and BCC carry an Hras1 mutation [171].

Expression peaks at early anagen [172].

Krt1-14

Altered expression in squamous cell skin cancer reflecting the
differentiation stage [173].

Expressed at anagen, early differentiation marker
[127].

Ivl

In epidermal papillomas, expression level correlates with degree
of histological differentiation [174].

Expressed during anagen, late differentiation marker
[127].

Pcna

Increased expression in squamous type skin cancers [175, 176].

Expressed in proliferating hair follicle cells [177, 178].

Pdgfa

Stimulates tumor cell growth, transformation [179, 180]; expressed
in many epithelial tumors [181, 182]; altered expression in
squamous cell cancer [183].

Expressed by both FK and DPC [182]; role in
formation of dermal papilla [184].

Plaur

Over-expression is correlated with tumor progression and
metastasis; expressed in squamous cell skin cancers [185].

Expressed in all cells of hair follicle [186].

Stat1

Constitutively active in many human tumors with Stat3 [187].

Increases promoter activity of Ivl, which is a
keratinocyte differentiation marker [188].

Stat3

Constitutively active in squamous cell cancers [183, 189, 190];
required for skin cancer development [190, 191].

Expressed during transition from telogen to anagen
stage [192].

Tert

Reactivated in 90% of human cancers [131]; telomerase-deficient
mice are resistant to skin carcinogenesis [193].

Rapid transition from telogen to anagen [131].
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Table 4. Differential expression levels of 10 selected genes in the skin of K14Agouti mice compared to control mice at various ages. Fold differences for each
gene between transgenic animals and their littermate controls are shown.
Expression levels that are significantly up-regulated in transgenic mice based on
qRT-PCR analysis are labeled in red. Expression levels that are significantly
down-regulated in transgenic mice are labeled in green, and expression levels
that do not differ significantly between transgenic and control mice are labeled in
blue. Shown in the bottom panel are the hair-follicle cycle stages corresponding
to the ages of C57BL/6 control mice based on the published literature [123]. The
genes were placed into two groups based on their age-related expression
patterns in control mice (see Fig. 7).
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Figure 7. Age-related differences in the expression patterns of 10 genes in the
skin of K14-Agouti mice. Gene expression levels in control mice (A and B) and
in K14-Agouti mice relative to control mice (C and D) were determined by qRTPCR analysis. For control mice in graphs A and B, the expression level of each
gene at 4.5 weeks-of-age was assigned the value of 1.0, and the expression
levels at later ages are reported relative to this value. In graphs C and D, the
relative fold differences between K14-Agouti and control mice are presented for
each age. In all graphs, the y-axis represents average fold differences in gene
expression levels (mean ± SEM), and the x-axis represents the age of mice in
weeks. In A and B, N= 2 at 4.5, 6.4, 6.6, 7.5, 10.4, 11.4, 12.5, and 26.5 weeks of
age and N=4 at 6.5, and 18.4 weeks of age. In C and D, N=4 at 4.5, 6.4, 6.6, 7.5,
11.4, and 12.5 weeks of age, N=8 at 6.5 weeks of age, N=6 at 10.4 weeks of age,
and N=2 at 26.5 weeks of age. Gene expression levels greater than 1.4 fold or
less than 0.72 fold (each indicated by a black horizontal line) indicate significant
changes in expression. Shown in the bottom panels are the hair-follicle cycle
stages corresponding to the ages of C57BL/6 control mice based on the
published literature [123].
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(Fig. 7, bottom panel). Thus, the wild-type expression levels of most Group I
genes were significantly up-regulated at a time when the hair follicles are in the
second postnatal anagen stage (Fig. 7A). Group II genes (Csnk2a2, Pcna, and Tert)
exhibited a cyclical wild-type pattern, with up-regulated expression possibly
coinciding with the transitions between different hair-follicle cycle stages, or
with other age-related differences in the skin (Fig. 7B).

Having determined the temporal expression patterns of these 10 genes in
control mice, we next determined the relative differences in the expression levels
of these genes in K14-Agouti mice compared to the control mice (Fig. 7C and D).
In K14-Agouti mice, Group I genes were significantly up-regulated at three
different time points (7.5, 10.4, and 12.5 weeks) (Fig. 7C). Thus, the expression
levels of Group I genes were normally up-regulated in control mice during
anagen, but in the K14-Agouti mice these genes were significantly overexpressed during telogen, prior to the onset of anagen, and also significantly
over-expressed at two time points during anagen. Group II genes in K14-Agouti
mice had more of a linear profile, showing uniform over-expression during most
of the hair-follicle cycle stages, including significant over-expression at telogen,
prior to the onset of anagen (Fig. 7D). Taken together, these data demonstrate
that 10 genes associated with cancer biology and/or cellular differentiation and
proliferation events exhibited dynamic patterns of gene expression in the skin of
control mice that change with age, and that their expression levels and patterns
are altered in the skin of tumor susceptible K14-Agouti transgenic mice.
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Examining Gene Expression Profiles in K14-Agouti Skin at
Precisely Determined Stages of the Hair-Follicle Cycle
Since the agouti protein is a secreted signaling molecule normally
expressed during anagen, we hypothesized that the observed differences in gene
expression in K14-Agouti mice could be caused in one of two ways. First,
constitutive over-expression of agouti could be impacting other signal
transduction pathways, resulting in the differential expression of these genes.
Second, over-expression of agouti could be altering the timing of the hair-follicle
cycle stages, which in turn would alter the expression of genes associated with
specific stages of follicle growth. To choose between these possibilities, we
synchronized the hair-follicle cycle for all follicles in the dorsal skin of eightweek-old K14-Agouti and control mice by hot wax epilation. At eight weeks of
age all dorsal skin hair follicles are in telogen, and epilation induces synchronous
anagen development of follicles over the entire epilated region, followed by the
spontaneous entry into catagen and telogen at defined times over a 25 day period
[123]. Mice were euthanized at eight time points (0, 3, 5, 8, 12, 17, 20 and 25 days)
after wax epilation, the precise stage of hair follicle development was determined
at each time point by histological examination of the skin and hair follicles, and
qRT-PCR analysis was performed for the 10 genes at each time point.

Histological analysis of the hair follicles in K14-Agouti mice following
synchronization showed no differences in hair-follicle cycle progress compared
to their littermate controls. Additionally, the timing of each hair-follicle cycle
stage for transgenic and control mice was consistent with the published literature
for female C57BL/6 mice (Table 5).
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Table 5. Progress of the hair-follicle cycle in K14-Agouti and C57BL/6J (B6)
control mice. The hair-follicle cycle stages in the dorsal skin of K14-Agouti mice
and C57BL/6J (B6) control mice are shown at eight time points (days) following
wax epilation. Two transgenic and two control mice were euthanized at each of
eight time-points post-epilation, and the stage of the hair-follicle cycle was
determined by histological analysis of the skin. The hair-follicle stages did not
differ between transgenic and control mice at any time, and they were also
essentially the same as previously published for C57BL/6 mice (Reference B6)
[123].
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Gene expression analysis of K14-Agouti and control skin following
epilation was performed by qRT-PCR. For each of the 10 genes, two temporal
expression profiles are shown for the eight time-points post-epilation; the wildtype pattern of expression in the control mice, and the relative fold differences in
gene expression in the transgenic mice compared to the control mice (Fig. 8). For
all genes except Stat3, wax epilation induced a significant up-regulation of wildtype gene expression in control mice at day 3 (early anagen), which generally
remained up-regulated at most subsequent time points. Notable among these
nine genes were the expression patterns of Tert and Pcna. Wild-type Tert
expression was up-regulated 3,000-fold on days 3 and 5 post-epilation (early
anagen), followed by expression levels that ranged between 3- and 8-fold upregulated on subsequent days. Wild-type Pcna expression was up-regulated 120fold on day 3 post-epilation and ranged between 57- and 138-fold up-regulated
on subsequent days.

The expression levels of 7 of the 10 genes (Csnk2a2, Hras1, Krt1-14, Ivl,
Pcna, Pdgfa, and Tert) in K14-Agouti skin were significantly up-regulated
compared to control levels immediately after wax epilation (day 0) when dorsal
hair follicles were in telogen (Figs. 8 and 9). The expression levels of 9 of the 10
genes were significantly down-regulated in K14-Agouti skin compared to control
skin during one time point in early or mid anagen (day 3: Csnk2a2, Pcna, Pdgfa,
Plaur; day 8: Hras1, Ivl, Stat1, Stat3, Tert) (Fig. 9). With a few exceptions, the
expression levels of the 10 genes in K14-Agouti skin did not differ significantly
from the levels in control skin at the remaining time points. Overall, the hairfollicle cycle synchronization experiments revealed that the initiation and
duration of the different hair-follicle cycle stages did not differ between K14Agouti transgenic mice and control mice. However, the expression levels of
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Figure 8. Temporal expression patterns of 10 genes in the skin of K14-Agouti
mice and control mice during specific stages of the hair-follicle cycle following
wax epilation. Gene expression levels in control mice (shown in blue) and in K14Agouti mice relative to control mice (shown in red) were determined by qRTPCR analysis. Each graph corresponds to a single gene, and the gene symbol is
shown in the top of the graph. For each of the 10 genes, the expression level in
control mice at day 0 after epilation was assigned the value of 1.0, and the
expression levels at later days are reported relative to this value. In addition to
the wild-type pattern of expression for each gene, the relative fold differences
between K14-Agouti and control mice are shown at each time point. In all
graphs, the y-axis represents average fold differences in gene expression levels
(mean ± SEM), and the x-axis represents the number of days following wax
epilation. Gene expression levels greater than 1.4 fold or less than 0.72 fold (each
indicated by a black horizontal line) indicate significant changes in expression.
Shown in the bottom panel are the hair-follicle cycle stages that correspond to
each time point after wax epilation, as determined by histological analysis of the
skin. N = 4; each gene analyzed in duplicated in two animals at each time point.
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Figure 9. Changes in the temporal profiles of 10 genes in the skin of K14-Agouti
mice compared to control mice following wax epilation. Genes are grouped
according to their differential expression levels at the start of the hair-follicle
cycle synchronization experiment and during the early and mid anagen stages of
the hair-follicle cycle. In K14-Agouti skin, seven genes were significantly upregulated at day 0, four genes were significantly down-regulated at day 3, and
five genes were significantly down-regulated at day 8.
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many genes that are normally up-regulated in early anagen in wild-type mice
were up-regulated at an earlier time point (telogen) in the transgenic mice.

DISCUSSION
The agouti protein was previously shown to act as a tumor promoter in
the skin of K14-Agouti transgenic mice since it promoted the development of
papillomas in two-stage skin carcinogenesis experiments, but only after the skin
was chemically initiated [99]. We speculated that high levels of constitutive
paracrine signaling by agouti protein in the skin of K14-Agouti mice might act as
a tumor promoter by in-turn up-regulating the expression of other protooncogenes. Here, our goal was to determine molecular level changes in the noninitiated skin of K14-Agouti transgenic mice using cDNA microarray and qRTPCR analyses. Since over-expression of agouti in the skin of K14-Agouti mice
acts as a tumor promoter and skin tumors do not develop in the absence of
initiation, we reasoned that any gene expression differences detected in the skin
will possibly be associated with the promotion stage of two-stage carcinogenesis.

Through microarray analysis we identified a total of 181 differentially
expressed genes that may be associated with the promotion stage of skin
carcinogenesis in K14-Agouti transgenic mice. Forty of the significantly upregulated genes and 29 of the significantly down-regulated genes have been
functionally annotated previously. According to their gene ontology terms, these
differentially expressed genes are primarily involved in the following cellular
processes: cell proliferation (Hras1, Pdgfa), regulation of progression through the
cell cycle (Csnk2a2, Pdgfa), signal transduction (Csnk2a2, Hras1, Plaur, Erbb2
interacting protein, Erbb2ip; guanine nucleotide binding protein (G protein),
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gamma 3 subunit, Gng3), protein phosporylation (Csnk2a2; PTEN induced
putative kinase 1, Pink1), regulation of peptidyl-tyrosine phosphorylation (Pdgfa),
DNA repair (RAD1 homolog (S. pombe), Rad1; excision repair crosscomplementing rodent repair deficiency, complementation group 3, Ercc3),
protein targeting/transport (Sec61 alpha 1 subunit (S. cerevisiae), Sec61a1,
adaptor protein complex AP-1, beta 1 subunit, Ap1b1; Erbb2ip; AP1 gamma
subunit binding protein 1, Ap1gbp1), ubiquitin-dependent protein catabolism
(ubiquitin specific peptidase 27, X chromosome, Usp27x; ubiquitin specific
peptidase 2, Usp2), regulation of transcription, DNA-dependent (zinc finger,
matrin-like, Zfml; cartilage homeo protein 1, Cart1; c-myc binding protein,
Mycbp), and the tricarboxylic acid cycle (malate dehydrogenase 1, NAD (soluble),
Mdh1; citrate synthase, Cs).
Alterations in the first three of these cellular processes — cell proliferation,
regulation of progression through the cell cycle, and signal transduction — are
known to be associated with the promotion stage of carcinogenesis. Csnk2a2,
Hras1, Pdgfa, and Plaur are each involved in at least one of these cellular
processes, they play important roles in many normal as well as pathological
processes, including carcinogenesis, and they were significantly up-regulated in
the skin of K14-Agouti transgenic mice. For these reasons, we selected Csnk2a2,
Hras1, Pdgfa, and Plaur for more detailed analyses, which included examining the
expression levels of these genes in the skin of K14-Agouti and control mice
ranging in age from about one month old to over six months old. We also
examined the expression levels of these genes in the skin of two-month-old K14Agouti and control mice during precisely determined stages of the hair-follicle
cycle over a 25 day period following synchronization of follicle development in
the dorsal skin by wax epilation. In these analyses, we also included four
markers of cellular proliferation and differentiation (Pcna, Tert, Krt1-14 and Ivl),
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and two transcription factors (Stat1 and Stat3) previously shown to be upregulated by ectopic agouti expression in adipose tissue [97]. All 10 genes under
investigation have previously been associated with epithelial carcinogenesis
and/or cellular differentiation, proliferation and hair-follicle cycle events, as
summarized in Table 3.
qRT-PCR analysis of these 10 genes in the skin of transgenic and control
mice over a wide range of ages revealed that, in all cases, both the expression
levels and age-dependent dynamic expression patterns of these genes were
altered in the skin of K14-Agouti mice. The wild-type expression levels of most
of these genes were normally up-regulated in the skin of control mice at 12.5
weeks of age, a time when dorsal hair follicles are in anagen, or the growth stage
of the hair-follicle cycle. However, in K14-Agouti mice, all of these genes were
significantly up-regulated compared to control levels at 7.5 weeks of age, a time
that corresponds to telogen, or the resting stage of the hair-follicle cycle. For the
majority of these genes, expression levels remained significantly elevated in the
skin of transgenic mice compared to control mice at 10.4 weeks (early anagen)
and 12.5 weeks (late anagen), but not at 11.4 weeks.
The major findings from the qRT-PCR analysis of these 10 genes in the
skin of transgenic and control mice during defined stages of the hair-follicle cycle
following epilation are that most of these genes were significantly up-regulated
in K14-Agouti skin compared to control skin at the telogen stage, prior to the
onset of anagen. In control mice, wax epilation induced telogen hair follicles to
enter anagen at three days post-epilation, which also caused a significant upregulation in the wild-type expression levels of 9 of the 10 genes (all except Stat3)
during early anagen (Fig. 8; 3 days post-epilation). These results were in
agreement with the age-dependent experiments (Fig. 7), where the wild-type
expression levels of these genes were also up-regulated in association with the
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transition from telogen to anagen. In K14-Agouti transgenic mice, wax epilation
also induced telogen hair follicles to enter anagen at three days post-epilation,
and there were no differences in hair-follicle cycling between transgenic and
control mice. However, seven of the 10 genes (Csnk2a2, Hras1, Krt1-14, Ivl, Pcna,
Pdgfa, and Tert) were significantly up-regulated in K14-Agouti skin compared to
control skin during telogen (Fig. 8; 0 days post-epilation). This result also
correlates with the age-dependent expression profiles of these genes (Fig. 7);
namely, that the expression of K14-Agouti in the skin of mice is inducing
significant up-regulation in the expression of genes associated with epithelial
carcinogenesis at an earlier time (telogen) and at abnormally elevated levels
compared to control mice.
For nine of the 10 genes (all except Krt1-14), there was a brief period
during early or mid anagen when their expression levels were significantly lower
in K14-Agouti mice compared to control mice. This result may be similar to what
we observed in mid anagen for the age-dependent experiments, where the
expression levels of most genes did not differ significantly between transgenic
and control mice in mid anagen (Fig. 7; 11.4 weeks). Unlike the age-dependent
experiments, where the expression levels of all genes were significantly upregulated in the skin of K14-Agouti mice in late anagen (Fig. 7; 12.5 weeks), the
expression levels of all genes did not differ significantly in transgenic and control
mice in late anagen following epilation (Fig. 8; 12 days). The reason for this
difference is unclear, but it suggests that, in the age-dependent experiments,
over-expression of these 10 genes in the skin of transgenic mice in late anagen is
associated with some age-dependent factor in the skin other than the stage of the
hair follicles.
Over-expression of K14-Agouti in the skin of transgenic mice had no effect
on the hair-follicle cycle based on histological analysis of the skin, but it did
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cause over-expression of numerous genes associated with epithelial cancers. Not
only were these genes over-expressed in the skin of transgenic mice at ages
associated with anagen, a time when these genes are normally activated in
control mice, they were also over-expressed in the skin of transgenic mice during
telogen, resulting in the exposure of transgenic skin and hair follicles to these
proto-oncogenes over a prolonged period of the hair-follicle cycle. These results
suggest that K14-Agouti may have a more direct role as a paracrine signaling
molecule in altering the expression of the genes under investigation.
Notable among the genes over-expressed in the skin of K14-Agouti mice
are Csnk2a2, Hras1, Pdgfa, Plaur, and Stat1. Csnk2a2 is one of the catalytic subunits
of protein casein kinase 2 (Ck2) [194]. CK2 is a pleiotropic, ubiquitously
expressed, protein Ser/Thr kinase with 307 known substrates [195], and involved
in many cellular functions, such as cell proliferation, division, and development
(reviewed in [196, 197]); cell survival [198]; inhibition of apoptosis [199, 200]; and
neoplasia (reviewed in [201]). The catalytic Csnk2a2 subunit also has oncogenic
activity [201]. Altered expression of Csnk2a2 results in the transformation of
mammary epithelium [169] and increases the transformation rate in fibroblasts
[202].
Activation of RAS proteins initiate different signal transduction pathways
that regulate cellular proliferation, transformation, differentiation, and apoptosis
(reviewed in [203, 204]). Over-expression of wild-type Ras or mutations that
constitutively activate Ras have been observed in a wide spectrum of cancers
[205-207] including skin cancer [208, 209]. Mutations in the Hras1 gene have been
observed in non-melonoma skin cancers with up to 20% frequency (reviewed in
[210]). Additionally, the skin of v-Ha-ras transgenic TG.AC mice has been shown
to have enhanced sensitivity to chemically induced tumorigenesis when there is
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ubiquitous over-expression of agouti protein due to the presence of the Avy allele
[21].
PDGF and its protein tyrosine kinase receptors have been linked to a
variety of disorders including carcinogenesis [203]. PDGF is a mitogenic protein
and its alpha chain is known to cause transformation in both autocrine [180, 211]
and paracrine fashions on its target cells (reviewed in [212]). Activation of
PDGFA signaling has been shown to be critical for the development of a wide
range of tumors such as glioblastoma, leukemia, gastro-intestinal carcinoma,
prostate and breast cancer, malignant melanoma, and squamous cell carcinomas
([181], reviewed in [179, 180, 183]).
PLAUR is also involved in a wide range of physiological functions, such
as regulation of cell surface plasminogen activity, cellular adhesion, cell motility,
angiogenesis, wound healing, tissue regeneration, tumor invasion, and
metastasis (reviewed in [213-215]). PLAUR and its ligand have been associated
with malignant transformation of the ovarian epithelium [216]. Elevated levels of
PLAUR have been reported in several malignancies ([217, 218], reviewed in [215,
219]), including squamous cell cancer of the skin [185, 220].
Although loss of STAT1 signaling has been shown in many human tumors
[221, 222], it has been found to be constitutively active in a variety human tumors
with STAT3 [188]. In squamous epithelial cells, aberrant activation of epidermal
growth factor receptor (EGFR) has been shown to constitutively activate both
Stat1 and Stat3 [189, 223]. Over-expression of these proto-oncogenes in the skin
of K14-Agouti mice are highly likely to play a role in K14-Agouti-induced skin
tumor promotion.
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In conclusion, we used cDNA microarray analysis to identify 181
differentially expressed genes in the skin of K14-Agouti mice. We used qRT-PCR
analysis to identify and quantify changes in the expression levels and temporal
profiles of 10 genes (Csnk2a2, Hras1, Krt1-14, Ivl, Pcna, Pdgfa, Plaur, Stat1, Stat3,
and Tert) in the skin of K14-Agouti mice, which have previously been associated
with epithelial neoplasia in other models. These genes were significantly upregulated in the skin of K14-Agouti mice during telogen, prior to the normal upregulation of these genes during anagen in control mice. These genes were also
over-expressed in the skin of K14-Agouti mice at ages associated with the anagen
stage of the hair-follicle cycle, a time when agouti is normally transiently
expressed in the skin and when mouse skin is known to be more susceptible to
carcinogenesis. Thus, the increased susceptibility to skin carcinogenesis observed
in K14-Agouti transgenic mice is proposed to be associated with the altered
expression levels and patterns of these genes. Further studies with the tumor
susceptible K14-Agouti mouse model will prove useful for extending these
findings and for determining the molecular genetic network through which the
unregulated activation of the agouti gene acts as a tumor promoter in skin
carcinogenesis.
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CHAPTER III
Conclusions and Future Perspectives

In mice carrying the spontaneous dominant mutations Ay or Avy,
ubiquitous over-expression of the agouti gene causes an increased susceptibility
to tumorigenesis in numerous tissues, including the skin. These mice are also
obese and diabetic because of ectopic agouti expression in the brain. In mice
carrying the albumin-Agouti or K14-Agouti transgenes, over-expression of the
agouti gene in the liver or skin, respectively, does not cause obesity or diabetes.
However, albumin-Agouti and K14-Agouti mice are significantly more
susceptible to liver or skin cancer, respectively, following chemical initiation of
the liver or skin. These data suggest that the agouti protein may act as a tumor
promoter in various tissues by directly impacting other signal transduction
pathways in the tissue in which it is expressed. Although the association between
the agouti protein and tumor susceptibility has been known for many decades
and the agouti gene was cloned 14 years ago, the molecular basis of the agouti
protein in tumorigenesis remains largely unknown. Therefore, the goal of my
research was to elucidate molecular mechanisms associated with agouti-induced
skin tumor promotion.
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In the previous chapter, cDNA microarray analysis was used to identify
significant changes in the expression levels of 181 genes in the skin of K14Agouti transgenic mice compared to non-transgenic control mice. Real-time qRTPCR experiments demonstrated that 10 genes previously associated with various
epithelial cancers exhibited dynamic patterns of gene expression in the skin of
control mice that changed with age, and their expression levels and patterns
were altered in the skin of tumor susceptible K14-Agouti transgenic mice. These
experiments provide significant insight into the potential role of the agouti
protein as a tumor promoter in skin carcinogenesis. Taken together, these data
suggest that over-expression of these proto-oncogenes in the skin of the
transgenic mice are possibly associated with the increased susceptibility of K14Agouti mice to skin carcinogenesis.

The genes with altered expression in K14-Agouti skin can be grouped by
gene ontology terms, which indicate the biological attributes of the gene and its
gene product. Among the cellular processes into which these genes are grouped,
the four with the greatest impact on tumorigenesis when they are altered in an
individual cell are cell proliferation, DNA repair, ubiquitin-dependent protein
catabolism, and energy metabolism. The agouti protein may act as a tumor
promoter by altering one or more of these cellular processes.

Based on the genes that have altered expression patterns in the skin of
K14-Agouti mice, an impact of agouti protein on cellular proliferation appears to
be the strongest candidate for the underlying molecular mechanism of agoutiinduced tumor promotion. For example, expression of the Pdgfa, Plaur, Stat1,
Stat3 and Hras1 proto-oncogenes was altered in K14-Agouti skin. These genes are
regulators of cell proliferation; they act through common signal transduction
pathways, and also interact with intracellular pathways downstream of agouti
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signaling, which are mainly described in adipocytes. Additionally, even though
there were no gross histological differences in the hair-follicle cycle between K14Agouti and control mice, there was an up-regulation of two cellular proliferation
markers, Pcna and Tert, in the skin of K14-Agouti transgenic mice.

Here, I present a further dissection and analysis of the microarray results,
and propose a model describing the main molecular mechanism for agoutiinduced skin tumor promotion. It should be noted that changes in gene
expression levels were measured in this study, but the model focuses on the
expected outcomes of changes in certain corresponding protein levels, which
were not measured in this study. The model depicts the main signaling pathways
impacted by agouti protein, the manner in which these pathways interact, and
how alterations in these pathways would lead to increased cellular proliferation,
which I suggest is the main molecular mechanism for agouti signaling in skin
tumor promotion. I also suggest future experimental approaches for validation of
the gene expression results at the protein level, and for testing of this model.

MODEL SIGNAL TRANSDUCTION PATHWAYS FOR
AGOUTI-INDUCED CELLULAR PROLIFERATION
Cells respond to different environmental signals (e.g., extracellular
ligands, environmental changes, etc.) through different signal transduction
pathways. The main components of a simple signal transduction pathway are an
extracellular signal, a membrane receptor, an intracellular secondary messenger,
and a transcription factor. Protein phosphorylation due to membrane receptor
activation by extracellular signals initiates the signal transduction cascade.
Protein tyrosine kinase (PTK), mitogen activated protein kinase (MAPK), and
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protein kinase C (PKC) are three major signal transduction pathways that
regulate

numerous

important

cellular

functions,

such

as

homeostasis,

proliferation, differentiation and pathophysiological processes. Constitutive
activation of these pathways often initiates intracellular signaling pathways that
lead to uncontrolled cellular proliferation and transformation [224].

Signal Transducer and Activator of Transcription (STAT)
Pathway
In the skin of K14-Agouti transgenic mice, a simple model for a signal
transduction pathway that could lead to cellular proliferation is the activation of
the protein tyrosine kinase (PTK) pathway, via platelet-derived growth factor
alpha (PDGFA) signaling through a PTK receptor and transduction of the signal
by STAT mediators (Fig.10). PDGFA is a potent mitogenic signal that initiates
intracellular signaling pathways, leading to cellular proliferation through protein
tyrosine kinase receptors [180, 211]. It activates PDGF receptor through ligandmediated dimerization and auto-phosphorylation of the tyrosine residues on the
cytoplasmic domain of the receptor. Some of the main downstream signal
transduction molecules for PDGFA receptors are the signal transducer and
activator of transcription (Stat) proteins [225].

Stat molecules moderate the cellular response to extracellular signals like
cytokines and growth factors by transmitting the signal from the cell surface
membrane to the nucleus. Upon activation of protein tyrosine kinase receptors,
Stats are recruited by the PTK receptor and phosphorylated at the tyrosine
residue. Phosphorylation of Stat molecules leads to homodimer or heterodimer
formation, which directs translocation of Stats into the nucleus. In the nucleus,
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Figure 10. Proposed mechanism for induction of STAT signaling in the skin of K14-Agouti transgenic mice. Upregulation of the three protein tyrosine kinase receptors (PDGFR, PLAUR, and PRLR) in the skin of K14-Agouti
mice is proposed to induce cellular proliferation through STAT signaling. The extracellular mitogenic signals are
delivered to the cells by Prolactin, PDGFA, and PLAU ligands, and transferred to the intracellular compartments
by activation of PTK receptors. Activated PTK receptors induce phosphorylation of STAT molecules.
Phosphorylated STAT molecules can form dimers and translocate to the nucleus, where they induce cellular
proliferation. All three PTK receptors are shown on the cellular membrane, which is drawn as a bi-layered dark
blue line. Semi-circular blue area represents the nucleus, and is surrounded by the nuclear membrane.
Phosphorylated forms of STAT molecules are labeled with the letter P, and tyrosine residues on STAT molecules
are marked with the letter Y. Solid arrows represent activation of signaling molecules.
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Stats directly bind to DNA to regulate transcription of target genes, depending
on the signaling pathway and the target tissue (reviewed in [226]). It has been
shown that PDGF signaling can induce phosphorylation of three STAT
molecules: STAT1, STAT3 and STAT5 (reviewed in [227]). Up-regulation of Pdgfa
expression due to ectopic over-expression of agouti might cause over-activation
the PTK signal transduction pathway through altered STAT activation, which is
important in skin tumor promotion.

STATs have been shown to be constitutively activated in skin papillomas
and SCCs [189]. Recent studies have suggested that STAT3 has an essential role
in two-stage skin carcinogenesis, and it is required during both initiation and
promotion events [190]. STAT3 activation through the epidermal growth factor
receptor (EGFR), which is a PTK receptor, during the promotion stage of skin
carcinogenesis has been shown to stimulate epidermal hyperproliferation [190].
Activation of EGFR and up-regulation of its ligands have been observed as a
common response to tumor promoting agents in mouse epidermis [228, 229].
Besides its own PTK receptors, PDGF can phosphorylate and activate EGFR [230,
231]. Transactivation of EGF signal by PDGF signaling has been shown to occur
through heterodimer formation of EGFR and PDFGR [232-234]. Thus, agoutiinduced over-expression of Pdgfa could result in altered signaling through both
PDGF and EGF receptors, which could result in increased cellular proliferation,
as shown in Figure 10.

Intracellular STAT signaling can also be activated by cytokine signals,
such as prolactin, through tyrosine phosphorylation of JAK kinases. Binding of
prolactin to the prolactin receptor (Prlr), which does not have any intrinsic
tyrosine kinase cytoplasmic domain, induces receptor dimerization, tyrosine
phosphorylation and activation of JAK kinase, and phosphorylation of Prlr [235].
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Even though it was not validated by qRT-PCR, our microarray data showed that
Prlr was up-regulated in K14-Agouti skin and had the fifth highest significance
score. In different cell lines and tissues, PRLR has been shown to activate STAT1,
STAT3 and STAT5. It has been suggested that prolactin activates STAT5 in a
different manner than it does STAT1 and STAT3 [236, 237].

Plasminogen

activator,

urokinase

receptor

(Plaur),

a

glycosylphosphatidylinositol-anchored receptor, is another gene up-regulated by
over-expression of agouti in the skin of K14-Agouti mice. PLAUR activation has
been shown to activate different signal transduction pathways, including PTK
[238], MAPK [239], and JAK/STAT pathways [240]. STAT1 activation through
PLAUR has been demonstrated in a human kidney epithelial tumor line [240],
and human vascular endothelial cells [241]. STAT1-STAT1 homodimers and
STAT1 heterodimers with STAT2 and STAT4 have been observed upon PLAUR
activation [242].

In the skin of K14-Agouti mice, up-regulation of the Pdgfa ligand, and
Plaur and Prlr receptors, could each result in altered activation of STAT
molecules that function in PTK pathways. Additionally, up-regulation of Stat1
and Stat3 were detected in the skin of K14-Agouti mice, which can directly
contribute to the altered STAT signaling. Thus, unregulated STAT activation in
the skin of K14-Agouti mice, caused by over-expression of agouti protein, is a
candidate intracellular signaling mechanism that may lead to altered cellular
proliferation (Fig. 10).

81

Mitogen Activated Protein Kinase (MAPK) Pathway
A variety of extracellular stimuli, such as environmental stress, mitogens,
cytokines, and neurotrophins can be transmitted to the nucleus through
intracellular mitogen activated protein kinase (MAPK) pathway signaling
cascades (reviewed in [203, 243, 244]). Although the mechanisms that control the
specificity of the cellular response to different stimuli through MAPK pathways
are still not clear, regulation of cellular proliferation through Ras-mediated
Raf/MEK/ERK signaling has been demonstrated in many studies (reviewed in
[171, 245-248]). One of the major activators of Ras/ERK signaling is the
phosphorylation of Ras by downstream mediators of PTK receptors [249]. Active
Ras recruits Raf-1 to the plasma membrane, where it will be activated by
phosphorylation [250]. In the next step of the cascade, Raf-1 directly activates
MEK, which is followed by ERK phosphorylation [251]. As discussed above,
PDGFA, PLAUR, and PRLR signals are activators of PTK signal transduction
pathways. For all three molecules, activation of the Raf/ERK signaling cascade
was previously proposed to explain effects of these signals on cellular
proliferation [235, 239, 252, 253].

The Hras1 proto-oncogene is up-regulated in the skin of K14-Agouti mice.
In addition to the activators of PTK signaling pathways, over-expression of wildtype Ras or activated Ras mutations is associated with tumorigenesis in different
tissues [205-209]. Ras/Erk is a target pathway in tumor promotion, as altered
regulation of mitogenic Ras/ERK signaling provides a growth advantage to the
target cells.

STAT activation, induction of the Ras/ERK MAPK pathway through PTK
receptors, and over-expression of Hras1 may be independent but interacting
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molecular mechanisms that could lead to altered cellular proliferation resulting
from altered agouti signaling (Figure 11).

Protein Kinase C (PKC) Pathway
Protein kinase C (PKC) signaling has been shown to induce the Raf1/MEK/ERK signaling pathway through activation of the Raf-1 molecule [254256], which has been proposed as the key mediator connecting PTK signaling
through growth factor receptors (such as PDGFR and EGFR) and PKC signals at
the cell membrane [257, 258].

PKC signaling has been implicated in the control of different cellular
functions, including cellular proliferation [249, 259, 260], and over-activation of
PKC signaling can result in cellular transformation [261-263]. The conventional
PKC isoforms, PKCα, PKCβ, and PKCγ, are diacylglycerol (DAG) sensitive, and
calcium responsive. This group of PKCs are activated by increased intracellular
Ca2+ levels due to Ca2+ influx through Ca2+ channels or due to release of Ca2+
from intracellular stores [264, 265]. PKC translocates to the membrane after
binding to Ca2+ to interact with DAG, which transforms PKC into a fully active
enzyme. PKCα has been reported to phosphorylate and activate Raf [251, 256,
266, 267], which then activates ERK and transmits a PKC-dependent proliferation
signal ([263, 268], reviewed in [269]).

Activation of PKC in response to a sustained increase in intracellular
calcium levels contributes to insulin resistance [249], which is also a possible
mediator for the insulin resistance observed in Avy mice [89, 270]. Similar to
calcium-mediated PKC activation in insulin resistance, agouti might be
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Figure 11. Intracellular signal transduction pathways proposed to be activated in K14-Agouti skin in response to
agouti signaling. Activation of two intracellular signal transduction pathways, STAT and RAF/ERK, are proposed
to induce cellular proliferation in K14-Agouti skin. STAT signaling can be activated through protein tyrosine
kinase receptors (PDGFR, PLAUR, and PRLR) (Fig. 10), which is labeled as PTKR. In this model, over-expression of
agouti is proposed to activate a calcium-dependent PKC pathway, which in turn can activate Ras-independent
ERK signaling. ERK signaling can also be initiated by activation of either PTKR or RAS molecules in the skin of
K14-Agouti mice. MCR, Ca2+ channels, and PTKRs are shown on the cellular membrane, which is drawn as a bilayered dark blue line. Semi-circular blue area represents the nucleus, and is surrounded by the nuclear membrane.
Phosphorylated forms of STAT molecules are labeled with the letter P and tyrosine residues on STAT molecules
are marked with the letter Y. Solid arrows represent activation of signaling molecules.
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activating PKC signaling through Ca2+-dependent pathways. Therefore, agoutiinduced cellular proliferation through PKC/ERK signaling is another mechanism
that may contribute to the tumor susceptibility phenotype in K14-Agouti, Ay, and
Avy mice (Figure 11).

Agouti-dependent elevation of intracellular Ca2+ has been observed in
several different cell types, such as skeletal muscle myocytes [93], adipocytes
[95], and pancreatic beta cells [271]. Agouti has been shown to act through both
Ca2+ transportation channel-dependent [95], and melanocortin receptordependent pathways [89] to increase intracellular Ca2+ levels. Although agouti
can act through both Ca2+ channels and melanocortin receptors for Ca2+dependent PKC activation, signaling through Ca2+ channels may be more likely
to explain the fact that over-expression of agouti throughout the body of Ay and
Avy mice causes increased tumor susceptibility in numerous tissues. For example,
agouti has been shown to cause a slow increase in intracellular Ca2+ levels only
through MC1R and MC4R receptors, which are expressed in the skin and
hypothalamus, respectively. On the other hand, Ca2+ channel receptors are
ubiquitously expressed in many different tissues. Thus, PKC activation through
Ca2+ channel receptors would not be limited to specific tissues, presenting a
molecular mechanism that could explain tumor susceptibility in different tissues
due to ectopic agouti signaling.
Agouti protein and the phorbol ester, 12-O-tetradecanoyl-phorbol-13acetate (TPA), are each tumor promoters in the skin of K14-Agouti mice.
Additionally, the agouti and TPA tumor promoters act synergistically in the skin
of K14-Agouti mice, decreasing the latent period of tumor formation and
increasing the cumulative prevalence, multiplicity, and malignant conversion
rate of skin papillomas [99]. It was suggested that agouti and TPA promote
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tumor development through independent pathways, but that these pathways
ultimately converge and lead to enhanced skin tumor promotion and
progression [99]. In addition to the activation of conventional calcium-dependent
PKCs by TPA, calcium-independent PKCδ can be induced in response to TPA
treatment. TPA has been shown to regulate cellular hyperplasia through PKCδ
induced Raf/ERK activation, as over-expression of c-Raf increases activation of
Ras-independent MAPK signaling in response to TPA treatment [255]. TPA and
agouti might be inducing independent intracellular signals through PKCδ and
calcium-dependent PKCs, respectively, which in turn could activate Ras/Erk
signaling in both cases. Therefore, the proposed mechanism for agouti-induced
cellular proliferation through Ca2+-dependent PKC activation might also be the
molecular basis of the synergistic action of TPA and agouti in tumor promotion.
The induction of the STAT, MAPK and PKC signaling pathways by
altered agouti signaling could each initiate cellular proliferation independently,
in an additive manner, or these three pathways might be interacting with each
other to amplify the cellular proliferation signal transmitted to the nucleus (Fig.
11).

Regulation of Gene Expression through Protein Kinase C
The Plaur, Pdgfa, Stat1, and Stat3 genes, which are up-regulated in K14Agouti skin due to over-expression of agouti, have also been shown to be
regulated at the transcriptional level by phorbol esters, specifically, by TPA.
Activation protein 1 (AP-1) is a group of transcriptional activator genes,
including the c-fos and c-jun oncogenes, which are the early responding genes to
TPA-induced PKC activation [272]. When activated, AP-1 proteins form dimers
through their basic region-leucine zipper binding motif, which can recognize and
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bind to TPA-response elements (TRE) found in the promoters of TPA-inducible
secondary response genes ([273], reviewed in [274]).

The PDGFA gene was shown to be induced by phorbol esters in human
glomerular mesangial cells [275] through TREs 1 and 2 in the promoter of
PDGFA ([276, 277], reviewed in [278]). Additionally, phorbol ester and TPAinduced activation of Plaur transcription has been shown during the promotion
stage of skin carcinogenesis, and in papillomas and carcinomas of mouse skin
[224, 279, 280, 281 ]. Plaur expression is induced in response to phorbol esters,
along with other urokinase genes, through PKC activation [279, 280]. Two
different AP-1 binding sites in the promoter region of human Plaur were
mapped, and induction of uPAR expression by phorbol esters was shown to
require the AP-1 binding site in colon cancer cells [282]. As they are induced by
the tumor promoting agent TPA, expression of urokinase genes by epithelial and
stromal cells has been suggested to have an impact on the early steps of tumor
promotion [220, 279].

In a recent study, activation of STAT1 and STAT3 transcription factors
was observed in skin papillomas and SCCs after topical treatment with different
tumor promoters, including TPA. In primary mouse keratinocyte cultures, an
EGFR-dependent activation mechanism was demonstrated for TPA-induced
Stat3 transcription. However, the involvement of TPA-induced PKC activation in
transcriptional regulation of Stat1 and Stat3 still needs to be determined [189].

Transcription of Pdgfa and Plaur were up-regulated in the skin of K14Agouti mice in response to the over-expression of agouti protein. TPA has been
shown to induce transcriptional activation of both Pdgfa and Plaur through
activation of PKC. Agouti and TPA act synergistically during the promotion
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stage of skin carcinogenesis in K14-Agouti mice [99]. Therefore, it is possible that
agouti-induced up-regulation of Pdgfa and Plaur transcription in the skin of K14Agouti mice might be occurring through a PKC-activated signaling pathway.
Up-regulation of the transcription of the Pdgfa and Plaur proto-oncogenes could
be inducing altered signal transduction through the STAT and MAPK pathways,
which could generate aberrant cellular proliferation signals.

In conclusion, I propose that agouti protein, like many other protooncogenes, may act as a tumor promoter by altering cellular signaling pathways
that induce the proliferation of initiated cells. In Figure 12, I present a model for
the role of agouti protein in cellular proliferation, which includes all of the
proposed intracellular signaling pathways and interactions that were discussed
above.

FUTURE PERSPECTIVES
In this study, I have shown differential expression of a set of genes in the
skin of tumor susceptible K14-Agouti transgenic mice that have known roles in
skin and/or other epithelial cancers. Based on the genes identified in these
experiments, on their established roles in normal cellular processes and common
signaling pathways, and on the known roles of agouti signaling in pigmentation
and obesity, I have proposed a hypothetical model to explain the role of the
agouti protein in tumor promotion. The model predicts that agouti may function
as a tumor promoter by altering various intracellular signaling pathways that
lead to unregulated cellular proliferation of initiated cells (Figure 12). Here, I
briefly describe several experimental approaches to test the validity of this model
and the proposed role of the agouti protein in tumor promotion.
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Figure 12: Proposed model for intracellular signaling pathways involved in
agouti-induced cell proliferation during tumor promotion. The main interactions
between three signaling pathways (calcium dependent PKC, Raf/ERK and
STAT) are shown in respect to each other. Genes that were found to be
differentially expressed in K14-Agouti skin are shown in red. Pathway activation
is represented with solid lines. Dashed lines indicate activation of gene
transcription. Over-expression of agouti signaling activates calcium dependent
PKC, which turns on transcription of Pdgfa and Plaur. Additionally, agouti
signaling might be activating the transcription of Stat1 and Stat3 through PKC
signaling. Altered levels of PDGFA and PLAUR proteins have the potential to
induce cellular proliferation through both STAT and RAS-RAF/ERK signal
transduction pathways. The RAF/EEK pathway can also be activated by PKC,
and by over-expression of the Ras proto-oncogene.
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In the proposed model, increased transcription of Pdgfa and Plaur in the
skin of K14-Agouti mice are considered to be the earliest events, which will then
trigger activation of STAT and Raf/Erk signaling, resulting in increased cellular
proliferation as determined by increases in the expression levels of cellular
proliferation markers. The sequential expression of these genes can be examined
by determining their order of activation after agouti stimulation of keratinocytes
in a cell culture system, which is a well-established in vitro model system to
study mouse skin biology and carcinogenesis [266, 283-286]. Changes in gene
expression patterns at different time points following treatment of keratinocytes
with recombinant agouti protein can be determined by qRT-PCR analysis.
Examining a time-course of gene expression differences in keratinocytes
following agouti stimulation would allow us to identify early and late
responding genes, and to test the proposed model. The most important finding
among the possible outcomes of this set of experiments would be the timing of
expression of Pdgfa and Plaur compared to the other genes. I would expect to
observe changes in the expression of Pdgfa and Plaur immediately following
agouti protein stimulation, while up-regulation of the proliferation markers, Pcna
and Tert, should occur at a later time for the proposed model to be valid.
Determining the exact timing and order of the regulation of Stat1, Stat3, Hras1,
Pcna and Tert will be helpful for fine-tuning the proposed interactions between
the various signaling pathways.

Establishing differential regulation of these genes in keratinocyte cultures
after treatment with recombinant agouti protein will provide us with a tractable
system for following and testing the effects of agouti protein on calcium, PKC,
and Raf/Erk signaling. First, it will be necessary to establish that treatment of
keratinocytes with recombinant agouti protein will induce an increase in
intracellular calcium levels (as it does in some other cell types), and activation of
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PKC and Raf/Erk molecules. Then each of these three intracellular signals can be
inhibited individually to determine their contribution to the overall picture, in
which the end results can be followed by the measurements of Pcna and/or Tert
expression, and cellular proliferation rates. During each inhibition experiment,
analysis of the regulation of gene expression and the changes in the activation
levels of the other two pathways will provide us with the necessary information
to elucidate the dependence of these events on each other. For example,
according to the model, when elevation of intracellular calcium is inhibited, PKC
and Erk signaling, and the expression of Pcna and Tert should not be activated to
the same levels as determined previously. Additionally, according to the
proposed model, agouti induces transcription of Pdgfa and Plaur through
activation of calcium-dependent PKC signaling. So, if this model is accurate, we
would not expect to see any significant changes in the transcription of Pdgfa and
Plaur in response to agouti signal when intracellular calcium and/or PKC
signaling is inhibited. On the other hand, inhibition of Erk signaling should not
affect the increase in intracellular calcium levels, the activation of PKC, or the
transcription of Pdgfa or Plaur after treatment of keratinocytes with recombinant
agouti protein.
Parallel to the experimental approaches described above, different
keratinocyte cell lines deficient for Hras1, Pcna, Pdgfa, Plaur, Stat1, Stat3, and Tert
can be generated in vitro by RNA mediated interference (RNAi), where long-term
post-transcriptional inhibition of targeted mRNA can be achieved by transfection
of cells with small interfering RNA duplexes (siRNA) expressed under the
control of RNA Polymerase III [287-290]. Observation of changes in the activation
of different signaling pathways, and regulation of other genes will provide
valuable information about the contribution of each gene in the different
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signaling pathways, and identify the key players of the proposed signaling
pathway.

Changes in gene expression levels determined by qRT-PCR should be
confirmed at the protein level. Additionally, analysis of the phosphorylation
status of STAT, RAF and ERK proteins would be important to determine their
activity levels. Western blot analysis is the classical approach for determination
of single protein expression and phosphorylation levels, which should be the
first choice in the analysis of a small set of genes, like in our experiments.
However, identification of overall changes in the protein expression levels, and
the post-translational modifications to these proteins with high-throughput
techniques will also be valuable. While complementing the results of the
microarray experiments, comparisons of changes in gene and protein levels will
provide additional important information about the regulatory dynamics of the
signaling pathways impacted by agouti signaling. Such comparisons may prove
useful for mapping the signaling networks associated with agouti-induced tumor
promotion [291].

Protein

arrays,

two-dimensional

differential

fluorescence

gel

electrophoresis (DIGE), and mass spectrometry are some of the high-throughput
approaches that can be used for protein expression profiling. Protein arrays are
produced by fixing antibodies on slides that are highly specific for their target
proteins. When these arrays are treated with protein samples from tissues or cell
cultures, proteins are bound by the antibodies to the array surface, which then
can be detected with systems such as the streptoavidin-biotin complex.
Comparison of protein binding levels between the experimental and control
samples allows detection of the differentially expressed proteins [292, 293]. In the
DIGE system, similar to cDNA microarray analysis, experimental and control
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samples are labeled either with Cy3 or Cy5. Following 2D gel electrophoresis,
where each protein is separated according to its charge and mass, each sample is
individually imaged and measurements are compared in order to determine the
expression levels of each protein in the experimental and control samples. An
additional advantage of the DIGE system is that it has the capacity for detecting
many

different

post-translational

modifications

of

proteins,

including

phosphorylation status [294]. DIGE analysis can be followed by mass
spectrometry technology for identification of proteins of interests. Additionally
different mass spectrometry approaches such as stable isotope labeling and
quantification using the absolute peptide ion intensity can be utilized for global
protein analysis and identification of differential protein expression profiles [295,
296].

Findings of these experimental approaches should help us to accept,
modify, or reject the proposed model. The new information gathered about
agouti signaling should be used to adjust the shortcomings of the proposed
model or to propose a new model.

After identification of the intracellular signaling pathways activated by
agouti protein, the next challenge will be to demonstrate the role of the described
signaling pathways in tumor promotion. Several of the reagents generated
during elucidation of the signaling pathways impacted by agouti protein can be
utilized in this effort. Comparison of in vitro cellular proliferation rates of agouti
treated keratinocytes in which calcium, PKC, or Raf/Erk signaling is inhibited
will be informative about the contribution of these signaling molecules on
agouti-induced cell proliferation. Furthermore, determination of changes in the
cellular proliferation rates in each RNAi keratinocyte cell line deficient for Hras1,
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Pcna, Pdgfa, Stat, Stat1, Stat3, or Tert will establish the individual roles of these
genes.

In vitro colony (focus) formation assays and in vivo transplantation of cells
into nude mice are widely used experimental approaches for the analysis of
tumorigenic capacity. These assays test the ability of cultured cells to form
tumors after growth in a semisolid agarose bilayer in a petri dish or in athymic
nude mice, respectively. In the colony formation assay, cells in culture started
from a single cell are grown in soft agar and the rate of colony formation is
measured. Similarly, cells can be injected subcutaneously into immunodeficient,
hairless mice and their tumorigenic capacity can be measured by monitoring the
formation of papillomas and squamous cell carcinomas. Since agouti is a tumor
promoter, the tissues or cell cultures that are over-expressing the agouti signal
will not give rise to increased numbers of tumors unless the cells are first
initiated. Therefore, to be able to measure the differences in the tumorigenic
capacities of the different cell lines in either assay, initiation of the cultured cells
will be necessary. In order to overcome these problems and ensure the stability
of introduced changes like gene silencing, and to eliminate the agouti treatment
of the cell cultures, K14-Agouti mice can be crossed with mice null for several of
the selected genes that showed potential to be the key players in agouti signaling
in the previous experiments. These new transgenic lines, which are overexpressing agouti in the skin but deficient for one of the agouti-regulated genes,
can be used for two-stage carcinogenesis. Any significant decrease in the rate of
papilloma formation after initiation of the skin with a single DMBA application
in the presence of over-expressed agouti signaling should demonstrate the
importance of the knockout gene(s) during tumor promotion.
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K14-Agouti transgenic mice represent a model system in which changes
associated with the tumor promotion stage of skin carcinogenesis can be
examined before the development of tumors. Such a model is useful for
elucidating molecular mechanisms associated with the promotion stage of
carcinogenesis. Since a large number of genetic changes will have occurred after
the development of a skin tumor, it can be difficult to determine which molecular
changes in tumors are associated with the promotion stage of tumor
development. Elucidating the molecular mechanisms associated with tumor
promotion is important, as tumor promotion is a reversible and rate-limiting
event in carcinogenesis. The studies described here will provide insights into the
mechanisms underlying agouti-induced tumor promotion. Ultimately, our goal
is to achieving a better understanding of the promotion stage of carcinogenesis,
which may provide new tools to better predict the risk factors associated with
carcinogenesis, and to develop mechanistic-based strategies for prevention and
treatment of cancer.
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Table A-1: List of significantly up-regulated EST clones

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

GenBank
Accession
BG069401
AW554157
BG064629
BG076699
BG069435
BG076669
BG069801
BG084801
BG068870
BG062978
BG078960
BG069400
BG068914
BG075404
BG066780
BG067185
BG070933
BG074710
BG067379
BG065574
AU045245
BG078140
BG075278
BG072416
BG081040
C78141
BG063752
BG072139
BG074480
BG065258
BG065416
BG075652
BG068523
AU040544
BG087899
BG073401

Score (d)
4.65
4.23
4.00
3.69
3.65
3.60
3.58
3.56
3.55
3.54
3.54
3.48
3.39
3.31
3.29
3.20
3.19
3.19
3.15
3.15
3.14
3.10
3.09
3.06
3.05
3.03
3.00
2.99
2.98
2.96
2.95
2.92
2.91
2.90
2.89
2.89

Fold
Difference
5.12
2.71
2.40
2.78
1.81
3.24
1.97
3.37
2.13
2.70
6.45
2.16
2.24
1.98
1.60
2.23
1.70
2.51
1.81
2.15
2.19
2.69
1.70
1.90
1.40
1.45
2.34
1.50
2.30
1.82
2.36
1.93
2.00
2.00
1.76
1.78
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Table A-1 Continued

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63

GenBank
Accession
BG075147
AW546368
BG074375
AW558391
BG074155
BG065550
BG075009
BG078271
BG063602
BG085480
BG077083
BG078778
BG074261
BG069140
BG070161
BG088153
BG075704
BG069963
AW559010
BG065751
BG073392
BG077751
BG063024
AW556849
BG064824
BG075661
BG069325

Score (d)
2.89
2.88
2.87
2.87
2.82
2.78
2.78
2.76
2.76
2.75
2.75
2.74
2.74
2.73
2.73
2.72
2.72
2.71
2.71
2.70
2.69
2.67
2.67
2.67
2.66
2.65
2.64

Fold
Difference
2.26
2.26
2.12
2.54
2.28
1.50
1.53
2.53
1.77
1.69
1.87
1.67
2.49
1.70
1.43
1.45
1.66
2.38
7.59
1.83
2.02
1.46
2.55
2.42
1.88
1.83
2.10
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Table A-2: List of significantly down-regulated EST clones

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

GenBank
Accession
BG080756
BG067459
BG069326
BG070908
BG068321
BG080961
BG070437
BG078393
BG068281
BG079049
BG063061
BG068227
BG067575
BG064789
BG080372
BG063376
BG088216
BG072510
AA408197
BG072581
BG071958
BG080565
BG064250
BG072525
BG066404
BG069987
BG083259
C85855
BG080525
BG070488
BG068092
BG065639
BG082362
BG072458
BG072229

Score (d)
-4.94
-4.85
-4.19
-3.88
-3.79
-3.73
-3.71
-3.67
-3.62
-3.60
-3.58
-3.52
-3.44
-3.41
-3.34
-3.23
-3.20
-3.18
-3.16
-3.15
-3.13
-3.10
-3.09
-3.09
-3.08
-3.06
-3.05
-3.02
-2.98
-2.96
-2.96
-2.95
-2.95
-2.94
-2.94

Fold
Difference
0.22
0.46
0.21
0.32
0.35
0.39
0.48
0.20
0.36
0.48
0.17
0.26
0.22
0.48
0.54
0.26
0.51
0.48
0.38
0.71
0.50
0.51
0.50
0.57
0.42
0.44
0.10
0.36
0.50
0.62
0.45
0.44
0.43
0.31
0.47
119
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36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71

GenBank
Accession
BG076569
BG080868
BG082009
BG067579
BG066639
AW558635
BG067060
BG069223
BG072807
BG067577
BG065984
BG067544
BG086567
BG063733
BG084279
BG066515
BG088837
BG070073
BG070961
BG066695
BG073477
BG066036:
C87415
AU018797
AU043030
BG068421
C80656
BG078783
BG082144
BG078394
BG066960
BG063430
BG064752
BG063715
BG082354
BG076744

Score (d)
-2.92
-2.91
-2.91
-2.90
-2.89
-2.89
-2.87
-2.86
-2.86
-2.86
-2.83
-2.82
-2.82
-2.81
-2.81
-2.80
-2.80
-2.80
-2.79
-2.79
-2.79
-2.78
-2.78
-2.76
-2.76
-2.75
-2.75
-2.75
-2.73
-2.71
-2.70
-2.69
-2.69
-2.68
-2.68
-2.67

Fold
Difference
0.28
0.33
0.38
0.28
0.22
0.40
0.61
0.27
0.42
0.63
0.49
0.61
0.50
0.32
0.48
0.39
0.48
0.42
0.24
0.42
0.13
0.47
0.56
0.21
0.41
0.33
0.56
0.50
0.67
0.43
0.61
0.38
0.50
0.53
0.43
0.37
120
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72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107

GenBank
Accession
BG067204
BG065962
BG083351
AW545830
BG067124
BG076025
BG069716
BI076595
BG066161
BG068687
BG066468
BG068412
BG084956
BG065203
BG086529
BG065689
BG069589
BG078672
BG088006
AW556334
BG067320
BG068547
BG081646
AW555555
BG068764
BG076373
AU018221
AU022767
BG075725
AU022997
BG066568
BG067890
BG068433
BG069583
BG073971
BG080589

Score (d)
-2.66
-2.65
-2.65
-2.64
-2.64
-2.64
-2.62
-2.61
-2.60
-2.60
-2.59
-2.59
-2.56
-2.55
-2.55
-2.53
-2.53
-2.51
-2.51
-2.50
-2.50
-2.50
-2.50
-2.49
-2.49
-2.49
-2.48
-2.48
-2.48
-2.47
-2.47
-2.47
-2.46
-2.46
-2.46
-2.46

Fold
Difference
0.42
0.50
0.25
0.62
0.26
0.59
0.60
0.54
0.48
0.49
0.33
0.58
0.49
0.45
0.64
0.62
0.40
0.44
0.59
0.15
0.57
0.29
0.53
0.44
0.40
0.48
0.54
0.20
0.57
0.38
0.38
0.49
0.52
0.62
0.35
0.38
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108
109
110
111
112
113
114
115
116
117
118

GenBank
Accession
AA408305
AW547303
BG067557
BG072014
BG083842
BG063053
BG065759
BG084201
BG068506
BG073713
BG083368

Score (d)
-2.45
-2.45
-2.45
-2.45
-2.45
-2.44
-2.44
-2.44
-2.43
-2.42
-2.42

Fold
Difference
0.36
0.40
0.62
0.67
0.60
0.33
0.69
0.43
0.73
0.59
0.62
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